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ABSTRACT 
Until recently, the main mechanism of argininosuccinate synthase (AS) regulation 
was described to exist mainly at the level of transcription. Transcriptional regulation of 
AS has been shown to be coordinate with eNOS in response to shear stress, hypoxia, 
tumor necrosis factor α (TNF-α), and PPAR γ agonist troglitizone. However, it is now 
understood that one level of NO regulation is cellular control of arginine availability to 
eNOS via post-translational modifications of AS such as phosphorylation. The purpose of 
this investigation was to determine under what conditions AS is phosphorylated at S328, 
identify the pathway that AS phosphorylation at S328 plays a role, and how 
phosphorylation affects AS function in endothelial cells. We developed a phospho-
specific antibody directed against pS328 AS and assayed for increases or decreases in 
phosphorylation relative to physiological factors. We found that AS phosphorylation at 
S328 occurred when endothelial cells were stimulated with physiological factors that 
stimulate nitric oxide production through calcium-dependent stimulation of eNOS. 
Furthermore, by utilizing kinase inhibitors and kinase knockdown experiments, we 
showed that phosphorylation at S328 significantly decreased when PKCα was knocked 
down, suggesting that S328 phosphorylation of AS is involved in PKCα signaling. In 
addition, by confocal microscopy, immunoprecipitation, and membrane fractionation, we 
showed that phosphorylation at S328 of AS promotes its co-localization with eNOS in 
the perinuclear region. These findings describe a novel pathway involving AS regulation 
xii 
 
of nitric oxide production, and may serve as a novel drug target in the restoration of 
vascular nitric oxide homeostasis. 
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INTRODUCTION 
Function of vascular endothelium 
 Until the mid 1970s, the vascular endothelium was thought to mainly act as a 
barrier to partition the lumen from other constituents of the vessel (1). Since 
cardiovascular disease has been the most common cause of death in the US for several 
decades (2), much research has been conducted to further investigate the role 
endothelium plays in vascular biology. It is now understood that the endothelium is a 
critical component of the vasculature in that it mediates multiple functions required for 
cardiovascular homeostasis. For example, endothelial regulated permeability allows the 
transmission of serum derived proteins (2) and via the transcellular pathway, and 
leukocytes (2) mainly via the paracellular pathway, to reach the underlying tissue. More 
recently, it has been established that leukocytes traverse the endothelium in a 
transcellular manner as well (2). In normal, non-inflamed vessels, the transcellular 
passage of plasma solutes and fluids, often mediated through endothelial caveolae, supply 
tissues with essential nutrients that enable cell signaling and survival(3). The paracellular 
pathway that usually mediates large protein and leukocyte transport at endothelial tight 
junctions mediates the delivery of immune cells to reach remote sites of inflammation 
upon tissue injury (4). However, in the event of vascular injury such as postischemic 
reperfusion, endothelial permeability is increased (5). This is commonly referred to as 
“leakage” and leads to tissue edema, thus impairing capillary flow and tissue gas 
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exchange (6). In addition, vascular injury can promote increased expression of 
endothelial adhesion molecules allowing excessive monocyte adhesion and infiltration to 
the vessel wall with subsequent atheroma formation (7).  
 
 In addition to solute and leukocyte transport, a critical role of the endothelium is 
to generate signaling factors that alter vasodilation and vasoconstriction of the vessel. 
Physiological factors produced by endothelial cells that lead to vasoconstriction include 
endothelin-1, angiotensin II, and reactive oxygen species (ROS) (8, 9). Relating to 
vasodilation, the primary molecular messenger responsible for decreasing vascular tone is 
the free radical nitric oxide (NO) (10). NO is highly reactive and cannot be stored, 
therefore its production requires a proximal relationship to its target (11). As a result, the 
concentration of NO is inversely proportional to the distance it travels from the site of 
production (12). Since NO is readily diffusible across plasma membranes, the production 
of NO affects SMC relaxation after it is produced by the endothelium. The molecular 
mechanism of NO mediated vasodilation requires the association of SMC soluble 
guanylyl cyclase (sGC) with endothelial NO to convert GTP to cyclic GMP (cGMP) (13). 
Protein kinase G activation occurs upon generation of cGMP and subsequently promotes 
efflux of calcium from SMCs, leading to contraction inhibition (13). In the absence of 
NO production, SMCs are in a hyper-constricted state that contributes to increased blood 
pressure or hypertension (14).  
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 Because endothelial NO production is so vital to the regulation of vasodilation, 
platelet aggregation, and leukocyte adhesion, endothelial dysfunction is defined by the 
reduced capacity to generate NO (15). Consequently, endothelial dysfunction is often the 
initial event in the atherosclerotic lesion cascade that ultimately leads to hypertension and 
vessel occlusion (16). A heme containing homodimer called endothelial nitric oxide 
synthase (eNOS) is responsible for catalyzing the conversion of arginine to citrulline and 
NO in endothelial cells (Reaction 1) (17).  
2 L-arginine + 3 NADPH + 3 H
+
 + 4 O2  2 citrulline + 2 nitric oxide + 3 NADP
+
 + 4 H2O (R1) 
Control of NO production occurs through the direct interaction of eNOS with 
caveolin-1 or the activated calcium sensor protein calmodulin (CaM). eNOS is held in an 
inactive state when bound to caveolin and (18), upon interaction with activated CaM, is 
subsequently displaced from caveolin. Interaction of eNOS with calmodulin promotes a 
conformational change in the eNOS homodimer that allows the electron flux required for 
NO production to occur (19). A number of mechanisms relating to dysregulation of 
eNOS catalysis can ultimately lead to endothelial dysfunction (20). 
 
Molecular mechanisms leading to endothelial dysfunction 
Since impaired NO generation plays such a significant role in vascular endothelial 
dysfunction, a number of pathologies are associated with insufficient NO bio-availability. 
Oxidative stress, a causative agent of endothelial dysfunction, results from altered 
intracellular signaling as a consequence of obesity, endothelial injury, or increased 
circulating inflammatory signals (21). Hypertension, atherosclerosis, vascular 
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complications of diabetes, and stroke represent clinical presentations of long term 
endothelial oxidative stress. Endothelial oxidative stress precipitates the onset endothelial 
dysfunction by interfering with the catalysis of eNOS, or interacting with NO itself to 
prevent its vasoactive characteristics (22). Oxidative stress is the result of increased ROS 
including superoxide (O2
.-
), hydroxide ion (OH
-
), hydrogen peroxide (H2O2), and 
peroxynitrite (ONOO
-
) (21). Increased intracellular ROS levels are generated by the 
mitochondrial electron transport chain, isoforms of NADPH oxidase, xanthine oxidase, 
cyclooxygenase, lipooxygenase, and uncoupled eNOS (23-25). The uncoupling of eNOS 
is defined by the production of ROS or reactive nitrogen species (RNS) rather than NO 
(26) due to insufficient arginine or reducing power from BH4 (reactions 2 -4) (17). 
2 O2 +  NADPH + H
+
  2 O2
-
 + NADP
+
 + 2H
+
 (R2) 
and/or 
O2 + NADPH + H
+
  H2O2 + NADP
+
 (R3) 
and/or 
O2
.-
 + NO  OONO- (R4) 
There are multiple mechanisms that can lead to the uncoupling of eNOS in 
endothelial cells, including increased oxidative stress that promotes S-glutathionylation, 
increased asymmetric dimethylarginine (ADMA) production, oxidation of co-factors, or 
low arginine levels (27-30). Oxidative stress often results in reduced NO availability 
through the oxidation of the required co-factors (tetrahydrobiopterin (BH4), NADPH, 
FMN, FAD) of eNOS leading to the generation of O2
.- 
 (27). S-glutathionylation is a post-
translational modification of proteins that serves as an adaptive response to high ROS 
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levels. eNOS S-glutathionylation can occur on cysteines 689 and 908 in response to 
oxidative stress, which also results in the uncoupling eNOS (27). In addition, the 
generation of ADMA, a competitive inhibitor of eNOS and biomarker for impaired 
vascular health, occurs in response to oxidative stress through increased protein arginine 
methyltransferase 1 (PRMT1) activity (31). ADMA concentration, and its inhibition of 
eNOS, can be reduced by serving as substrate for dimethylarginine 
dimethylaminohydrolase (DDAH) (32). An increase in PRMT1, a decrease in DDAH 
activity, or altered balance between ADMA and arginine levels can consequently be 
detrimental to endothelial function. As a result, maintaining available arginine 
concentration for eNOS catalysis is critical in NO generation as well as preventing ROS 
production. Therefore, the prevention of oxidative stress, adequate arginine/ADMA ratio, 
and the maintenance of co-factors in their reduced form are important in supporting 
endothelial function through the prevention of eNOS uncoupling. 
 
eNOS regulation 
As a consequence of the fact that uncontrolled eNOS activity can potentially be 
damaging to the endothelium, eNOS is extensively regulated at the level of transcription, 
through protein-protein interactions, as well as post translational modifications such as 
phosphorylation, nitrosylation, and palmitoylation/ myristoylation, in order to modulate 
eNOS activity as well as its subcellular targeting (33, 34). In addition, there are two 
fundamental mechanisms of eNOS activiation, one is termed calcium-dependent, and the 
other is calcium-independent (35, 36). During calcium-dependent activation, the 
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stimulation of eNOS activity occurs through the direct interaction with activated 
calmodulin (37). However, during calcium-independent activation, a series of 
phosphorylation events occur that promote eNOS interaction with the activated 
calmodulin that exists at basal calcium levels (38). Several phosphorylation sites of 
eNOS have been identified, including S114, T495, S633, and S1177 (human sequence; 
S116, T497, S635, and S1179 bovine sequence), with T495 and S1177 being the most 
characterized (39). For bovine eNOS, the phosphorylation site T497 lies in the 
calmodulin binding region and thus prevents calmodulin interaction and eNOS activity 
when phosphorylated to reduce eNOS activity (40). Conversely, phosphorylation at 
S1179 discourages phosphorylation at T497 and thus promotes calmodulin-binding and 
increases eNOS activity. Thus, calcium-independent activation of eNOS occurs by 
promoting dephosphorylation of T497 and phosphorylation of S1179, rendering the 
enzyme more susceptible to basal levels of activated calmodulin (38).  
 
Multiple protein-protein interactions also modulate eNOS regulation. Evidence 
suggests that interaction with other proteins may play a role in eNOS targeting. For 
example, Schilling et al (41) described two novel eNOS-interacting proteins named 
NOSIP (for eNOS-interacting protein) and NOSTRIN (for eNOS-trafficking inducer), 
both of which influence the subcellular localization of eNOS. For NOSIP, targeting of 
eNOS to the cytoskeleton seems to be one of the protein’s major functions (42). On the 
other hand, when NOSTRIN is overexpressed, this leads to the translocation of eNOS 
from the plasma membrane to intracellular vesicular structures (43) possibly involving an 
endocytic process (44) 
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 In addition to phosphorylation or protein-protein interactions that regulate eNOS, 
regulation of substrate availability is a critical aspect of eNOS regulation. The Michaelis-
Menten constant (Km) of eNOS is in the 3-5 µM range, however the total cellular arginine 
concentration is in the 100-800 µM range, yet eNOS is rarely saturated with substrate, a 
phenomenon termed the “arginine paradox” (45). An explanation for the arginine paradox 
that is supported by findings in our laboratory and others is the existence of a subcellular 
pool of arginine that is accessible by eNOS, while bulk cellular arginine is not accessible 
(46-48). The maintenance of the arginine pool fated for eNOS catalysis is regulated by 
the arginine recycling enzymes argininosuccinate synthase (AS) and argininosuccinate 
lyase (AL) (49). AS, an ATP-dependent aspartate/citrulline ligase, catalyzes the rate 
limiting step of eNOS derived citrulline to argininosuccinate in endothelial arginine 
recycling (Reaction 5) (50, 51).  
Aspartate + Citrulline + ATP + MgCl2  Argininosuccinate + AMP + PPi (R5) 
2 Argininosuccinate  Fumarate + Arginine (R6) 
AL converts argininosuccinate generated by AS to the arginine that is ultimately directed 
to eNOS (Reaction 6) (51). The citrulline to arginine recycling by AS, AL, together with 
NO production by eNOS is referred to as the citrulline-NO cycle (52, 53).  
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Arginine recycling and NO production* 
AS expression is critical for the production of endothelial NO. The indication that 
AS plays an essential role in supporting NO production developed from a series of 
experiments using RNA interference to specifically silence AS expression in vascular 
endothelial cells (54).Diminished levels of AS expression that resulted from siRNA 
treatment were shown to correlate with impaired NO production in the presence and 
absence of effectors (54). Unanticipated, however, was the significant loss of viable 
endothelial cells observed after siRNA treatment. The fact that the loss of viability 
followed reduced expression of Bcl-2, and an increase in caspase activity, strongly 
suggested a relationship between impaired NO production and apoptosis. This 
relationship was supported by the observation that exposure to a NO donor rescued cell 
viability despite siRNA treatment (54). More importantly, these results demonstrated that 
AS was required for the maintenance of basal production levels of NO in order to support 
cell viability. In endothelial cells, AS and AL were shown to colocalize with eNOS and 
specialized structures of the plasma membrane called caveolae (55, 56). Caveolar 
domains assemble at the Golgi and traffic to the plasma membrane as stable transport 
platforms (57).This may explain the subcellular association of eNOS with the Golgi and 
perinuclear membrane (58-60).  
 
AS regulation and NO production* 
Although there has been much research conducted in the area of eNOS regulation, 
AS regulation has not been fully explored. Early research from the 1970s revealed that 
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hepatic AS is a critical component of the urea cycle (50). However, since the early 
publications on AS, our understanding of the properties and biological role of this 
enzyme has changed greatly. Initially, the non-hepatic role of this enzyme was assumed 
to be minimal; and as such, the role and regulation of AS, outside of that needed for urea 
production, developed slowly. However, interest in AS, and particularly its regulation, 
has grown due in great part because of its involvement in NO production (52). In 
humans, there are 15 copies of the AS gene, including 14 pseudogenes scattered across 
the genome (61). The ASS1 gene, located on chromosome 9, appears to be the only 
functional gene involved in AS expression. This is supported by the findings that 
mutations in the chromosome 9 copy of ASS1 cause citrullinemia (62-64). 
 
The AS promoter 
About 800 bp of the promoter region for the human ASS1 gene have been 
characterized (65) showing a TATA box, six potential Sp1 binding sites (GC boxes) and 
one potential AP-2 site (65, 66). The three GC boxes in the immediate promoter were 
shown to act synergistically and to be required in order to achieve full promoter 
activation (66). Surprisingly, no CAAT sequence (C/EBP binding site), nor GRE 
(glucocorticoid-responsive), or CRE (cAMP responsive-) elements were found in the 
early characterization of the AS promoter. Recently, however, Guei et al (67), through 
functional analysis of DNase I hypersensitive sites, located a cAMP response element for 
the human ASS1 gene at ~10 kb upstream of the transcription start site. This discovery 
helped reconcile earlier findings showing liver-specific enhancement of ASS1 gene 
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expression by TSE1 (tissue-specific extinguisher locus 1) regulation (68, 69), and the fact 
that transcription of the ASS1 gene in rat liver was stimulated by cAMP in nuclear run-on 
assays (70). TSE1 encodes the regulatory subunit Rl alpha of protein kinase A (PKA) 
(71). According to Tsai et al (72), the proximal region of the ASS1 promoter also contains 
an E-box that is recognized by c-Myc and HIF-1alpha, as well as a GC-box that is 
recognized by Sp4 in melanoma cells. Under non-induced conditions, the E-box element 
bound HIF-1 alpha, and under induced conditions (arginine depletion) HIF- 1 alpha was 
replaced by c-Myc, at least in two of the melanoma cell lines, but not in another (72). In 
all cases, however, Sp4 was shown to constitutively bind the GC-box regardless of 
arginine availability. Taken together, their results suggested that the transcriptional 
induction of ASS1 expression, relative to arginine depletion, involved the interplay 
between the positive transcriptional regulators c-Myc and Sp4, and the negative regulator 
HIF-1alpha. 
 
AS regulation by endothelial signaling 
Since most all phenotypic properties of endothelial cells relate to nitric oxide 
signaling, eNOS has been highly studied in response to physiological cues such as shear 
stress and cytokines (73-76). On the other hand, relatively little is known about the 
regulatory mechanisms that control AS expression in this context. Nevertheless, what has 
been elucidated, thus far, has provided a picture that supports the central role of AS and 
its coordinate regulation with eNOS in nitric oxide production. For example, Mun et al 
(77) examined the differential expression of genes in human umbilical vein endothelial 
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cells (HUVECs) under static and laminar shear stress conditions. Among the 20 genes 
whose expression was increased by laminar shear stress conditions, and simultaneously 
decreased by cellular senescence, was ASS1. Based on their findings, the authors 
suggested that AS expression was critical both for basal and laminar shear stress-induced 
nitric oxide production. This observation was consistent with Goodwin et al  (54) who 
demonstrated through siRNA knockdown studies, that AS expression was required to 
support both basal and induced nitric oxide production in vascular endothelial cells. 
Goodwin et al (78) also showed that both AS and eNOS expression were significantly 
reduced by treatment with physiological levels of TNF-alpha in vascular endothlelial 
cells. Not surprisingly, the loss AS and eNOS expression was accompanied by a dramatic 
decrease in the capacity of the TNF-alpha-treated cells to produce nitric oxide. Moreover, 
the down regulation of AS expression by TNF-alpha was shown to be mediated through a 
similar transcriptional mechanism by which TNF-alpha down-regulates eNOS, involving 
Sp1/Sp3 elements in the proximal promoter (73). Inhibitor studies suggested that 
repression of AS expression by TNF-alpha was mediated, at least in part, via the NF-
kappaB signaling pathway (79). Critically, these results revealed the extent to which 
TNF-alpha impairs vascular endothelial function via the coordinate down-regulation of 
both eNOS and AS expression (78). On the other hand, the peroxisome proliferator-
activated receptor gamma (PPAR-gamma) agonist, troglitazone, was shown to support 
nitric oxide production in vascular endothelial cells through the up-regulation of AS 
expression (80). Because the induction of AS was inhibited by treatment with the 
transcriptional inhibitor, 1-D-ribofuranosylbenzimidazole (DRB), this demonstrated that 
troglitazone mediated its response essentially at the transcriptional level. In keeping with 
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this finding, a distal PPAR-gamma response element (PPRE) at –2471 to –2458 was 
identified that mediated the PPAR-gamma agonist response. These results extended the 
repertoire of mechanisms by which PPAR-gamma agonists promote vascular health (81, 
82). In the case of troglitazone, one of its vascular protective properties directly relates to 
the maintenance of an adequate supply of arginine for nitric oxide production through the 
up-regulation of AS (80). Less is known at a more global level involving co-regulators 
and co-repressors that interact with specific transcription factors on the ASS1 gene 
promoter to alter rate of expression.  Thus, critical information related to the interplay of 
promoter elements that allow tissue specific expression of AS is quite limited.  
 
Regulation of AS localization 
AS has been shown to associate with raft-like membrane microdomains, caveolae, 
at the plasma membrane (55). The major constituent of caveolae is caveolin-1 (83), 
which is expressed in many cell types, including endothelial and epithelial cells. 
Importantly, a major phenotype of caveolin-1 knockout mice relates to nitric oxide 
signaling.  Nitric oxide release from caveolin-1-deficient cells is higher compared to 
wild-type cells, and secondary effects of nitric oxide are increased, demonstrating 
activation of eNOS through de-inhibition in the absence of caveolin-1 (84). Conversely, 
direct binding of eNOS to the scaffolding domain (positions 82-101) of caveolin-1 has 
been shown to decrease nitric oxide production in vitro and in cell culture (18, 56, 85). 
However, little is known as to whether caveolin may play a similar role in affecting either 
the activity or the subcellular localization of AS. Indeed, the only known factor shown to 
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affect localization of AS is citrin, a mitochondrial aspartate/ glutamate carrier that 
interacts with AS. Mutations in the SLC25A13 gene that encodes citrin were shown to 
cause adult-onset type II citrullinemia (63). In this case, the mutated citrin does not allow 
AS mitochondrial association. As a consequence, AS appears to be rapidly degraded 
accounting for the low levels found in hepatocytes of affected individuals (63). 
 
ARP regulation of AS 
Open reading frames in the 5´-leaders of messenger RNAs are emerging as 
important mediators of transcript-specific translational
 
controls. In most instances, 
upstream open-reading frames (uORFs) regulate the expression of a downstream ORF on 
the same mRNA (cis-regulation). In this case, those mRNAs with uORFs are typically 
expressed as the only species of that mRNA in a particular cell type (86). In contrast, the 
transcription of AS mRNA, at least in vascular endothelial cells, is initiated from multiple 
start sites, generating mRNAs with different lengths and overlapping 5´-untranslated 
regions (UTRs) (87). In fact, nearly 10% of argininosuccinate transcripts are longer 
variants that contain an out-of-frame, upstream open reading frame (uORF) encoding a 
~2.2 kDa protein, referred to as AS Regulatory Protein (ARP). ARP downregulates AS 
expression in trans at the translational level (88). Consistent with the rate-limiting role of 
AS in the citrrulline/nitric oxide cycle, the increase in AS protein that resulted from the 
knockdown of ARP was accompanied by an increase in nitric oxide production. 
Likewise, when ARP was over-expressed in endothelial cells, AS expression was 
suppressed, resulting in reduced nitric oxide production (88). 
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AS regulation by post-translational modification and protein-protein interaction 
Since AS is responsible for maintaining the available arginine for varied 
metabolic processes, it seems logical that acute or immediate changes in activity may also 
be necessary to accommodate the multiple roles that the arginine product plays in cell 
function. However, such immediate responses require regulation that goes beyond 
changes in transcription. Nevertheless, there are very few documented reports that 
discuss posttranslational events that may regulate the function of AS. In fact the bulk of 
literature suggests that AS regulation occurs primarily at the transcriptional level (52). 
There are, however, some recent findings that have changed this view. For example, it 
has been reported that the NADPH sensor protein, HSCARG, interacts with AS to 
downregulate its activity in epithelial cells (89). In fact, it has been suggested that the 
protein-protein interaction of HSCARG with AS may provide a mechanism by which the 
epithelial cell maintains an intracellular balance between its redox state and nitric oxide 
levels. On the other hand, Hao et al (90) showed that human AS can be inactivated by 
reversible nitrosylation at Cys-132 in response to lipopolysaccharide-treatment in both 
cultured smooth muscle cells and in mice. Mutagenesis studies confirmed that the 
nitrosylation of Cys-132 was both necessary and sufficient to inhibit AS. Based on their 
results, the authors suggested that post-translational modification of AS by nitrosylation 
might provide important feedback mechanism whereby nitric oxide can limit arginine 
availability in nitric oxide producing cells (90). Possibly the first report demonstrating 
that argininosuccinate was a phosphoprotein came in 2008 when Imani et al (91), using a 
phospho-proteomic analysis, reported that AS in HeLa cells was a phosphoprotein. 
However, their study did not consider the biological relevance of AS phosphorylation. 
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Subsequently, Corbin et al  (92) showed that AS was indeed phosphorylated in vascular 
endothelial cells in response to VEGF treatment by protein kinase A (PKA). 
Interestingly, PKA was already known to enhance nitric oxide production via 
phosphorylation and activation of eNOS (59). Although reports on the post-translational 
regulation of AS are presently meager in number, it is becoming clear that there exists an 
assortment of new mechanisms that affect AS expression and activity. As such, AS offers 
a distinctive paradigm for regulation that has expanded beyond transcriptional regulation 
to now include localization, transcriptional, and post-translational controls. This array of 
regulatory strategies which a cell uses to define and control arginine levels further 
endorses the physiological significance of AS in mammalian endothelial homeostasis. 
 
Specific Aims 
Purpose 
  It has been demonstrated that eNOS requires arginine derived from arginine 
recycling enzymes that is distinct from the bulk intracellular arginine pool, and without 
AS expression, NO production does not occur and endothelial cells do not survive (54). 
AS and eNOS have been isolated from caveolar fractions which suggests that arginine 
recycling and eNOS catalysis of arginine must take place in proximity in order to 
generate NO (55). eNOS associates with different compartments in the cell such as the 
golgi apparatus, the plasma membrane, mitochondria, and the cytosol (93-95). Various 
phosphorylation events as well as lipid modifications facilitate the translocation of eNOS 
to its respective compartment where NO production is needed (96). It is known that AS 
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and eNOS are transcriptionally co-regulated in response to various physiological factors. 
Importantly, Corbin et al have shown that AS exists as a phospho-protein in endothelial 
cells, however the biological significance of this is not known (92). We have identified a 
phosphorylation site at serine 328 (S328) of AS. The purpose of this research is to 
identify the biological relevance of AS phosphorylation at S328 in order to further 
characterize mechanisms by which AS contributes to NO production in endothelial cells. 
The understanding of how eNOS is regulated through substrate availability in different 
compartments of the cell will provide new insight for identifying novel therapeutic 
targets in the treatment of cardiovascular disease and diabetes. 
 
Central Hypothesis 
  Our central hypothesis is that AS is regulated by phosphorylation at S328 in 
endothelial cells in order to mediate spatial and/or temporal regulation of the enzyme in 
response to physiological cues that change the demand for NO (see working model, 
Figure 1). 
 
Specific Aim 1  
Determine how physiological factors affect AS phosphorylation at S328 in 
endothelial cells in relation to NO production. Endothelial nitric oxide synthase 
(eNOS) is regulated post-translationally by phosphorylation in a spatial and temporal 
manner to direct the amount and location of NO production in response to physiological 
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factors (42). In addition to post-translational modification, eNOS is also regulated by 
substrate availability (97). It is known that AS catalyzes the rate-limiting step in 
citrulline-NO cycle (55, 98), however the post-translational regulation of AS relative to 
physiological factors is largely unknown (92). We have previously identified serine 328 
(S328) as a phosphorylation site of AS through mass spectrometry analysis, in silico 
modeling, and subsequently developed a phospho-specific antibody against pS328. In this 
specific aim, we investigated the conditions by which AS is phosphorylated at S328. Our 
hypothesis for this aim was that AS is coordinately regulated with eNOS through 
phosphorylation at S328 in order to efficiently and acutely respond to the cellular demand 
for NO (described in Part I). 
 
Specific Aim 2 
  Identify the relevant kinase(s) involved in phosphorylating AS at S328 in 
endothelium in response to physiological factors. eNOS is regulated by 
phosphorylation events prompted by physiological factors that signal to endothelial cells 
to enhance or reduce NO production. Early evidence suggested that S328 was 
coordinately regulated with the inactivating phosphorylation at threonine 497 (T497) of 
eNOS. In this specific aim, we determined the kinase responsible for phosphorylating 
S328. Our hypothesis was that kinases that target eNOS at T497 are responsible for 
modifying S328 of AS (described in Part II). 
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Specific Aim 3  
Determine the effects of phosphorylation at S328 on AS activity and subcellular 
localization. Some caveolin binding proteins, including eNOS, are known to associate 
with lipid raft invaginations at the plasma membrane called caveolae (56) (99). Previous 
data showed that AS interacts with caveolin under stimulatory conditions, and S328 of 
AS resides 3 amino acids away from a putative caveolin binding motif. In this aim, we 
investigated the effect of S328 phosphorylation on AS interaction with caveolin and AS 
enzymatic activity. Our hypothesis was that AS phosphorylation at S328 will prevent 
interaction with caveolin in order to regulate AS localization rather than enzymatic 
activity (described in Part III). 
* sections have been published in peer-reviewed journal; Haines, R. J., Pendleton, L. C., 
and Eichler, D. C. (2011) Argininosuccinate synthase: at the center of arginine 
metabolism. Int J Biochem Mol Biol 2, 8-23 
 
References 
1.   Thorgeirsson G & Robertson AL, Jr. (1978) The vascular endothelium- 
pathobiologic significance.  Am J Pathol 93(3):803-848. 
2. Roger VL, et al. (2011) Heart disease and stroke statistics--2011 update: a report 
from the American Heart Association.  Circulation 123(4):e18-e209. 
3. Bell FP, Adamson IL, & Schwartz CJ (1974) Aortic endothelial permeability to 
albumin: Focal and regional patterns of uptake and transmural distribution of 
19 
 
131I-albumin in the young pig. Experimental and Molecular Pathology 20(1):57-
68. 
4. Meyrick B, Hoffman LH, & Brigham KL (1984) Chemotaxis of granulocytes 
across bovine pulmonary artery intimal explants without endothelial cell injury. 
Tissue & cell 16(1):1-16. 
5. Dvorak AM, et al. (1996) The vesiculo-vacuolar organelle (VVO): a distinct 
endothelial cell structure that provides a transcellular pathway for 
macromolecular extravasation.  J Leukoc Biol 59(1):100-115. 
6. Predescu SA, Predescu DN, & Malik AB (2007) Molecular determinants of 
endothelial transcytosis and their role in endothelial permeability.  Am J Physiol 
Lung Cell Mol Physiol 293(4):L823-842. 
7. Zeng G & Chen ZW (Neutrophils, reverse traffic and detrimental potential.  Cell 
Mol Immunol 9(2):99-100. 
8. Khandoga AG, Khandoga A, Anders HJ, & Krombach F (2009) Postischemic 
vascular permeability requires both TLR-2 and TLR-4, but only TLR-2 mediates 
the transendothelial migration of leukocytes.  Shock 31(6):592-598. 
9. Nedrebo T, Reed RK, & Berg A (2003) Effect of alpha-trinositol on interstitial 
fluid pressure, edema generation, and albumin extravasation after ischemia-
reperfusion injury in rat hind limb.  Shock 20(2):149-153. 
10. Nakashima Y, Wight TN, & Sueishi K (2008) Early atherosclerosis in humans: 
role of diffuse intimal thickening and extracellular matrix proteoglycans.  
Cardiovasc Res 79(1):14-23. 
20 
 
11. Vanhoutte PM, Feletou M, & Taddei S (2005) Endothelium-dependent 
contractions in hypertension.  Br J Pharmacol 144(4):449-458. 
12. Versari D, Daghini E, Virdis A, Ghiadoni L, & Taddei S (2009) Endothelium-
dependent contractions and endothelial dysfunction in human hypertension.  Br J 
Pharmacol 157(4):527-536. 
13. Furchgott RF (1996) The 1996 Albert Lasker Medical Research Awards. The 
discovery of endothelium-derived relaxing factor and its importance in the 
identification of nitric oxide.  JAMA 276(14):1186-1188. 
14. Bredt DS & Snyder SH (1994) Nitric oxide: a physiologic messenger molecule. 
Annu Rev Biochem 63:175-195. 
15. Arzumanian V, Stankevicius E, Laukeviciene A, & Kevelaitis E (2003) 
[Mechanisms of nitric oxide synthesis and action in cells]. (Translated from lit) 
Medicina (Kaunas) 39(6):535-541 (in lit). 
16. Nossaman B, Pankey E, & Kadowitz P (Stimulators and activators of soluble 
guanylate cyclase: review and potential therapeutic indications.  Crit Care Res 
Pract 2012:290805. 
17. Gewaltig MT & Kojda G (2002) Vasoprotection by nitric oxide: mechanisms and 
therapeutic potential.  Cardiovasc Res 55(2):250-260. 
18. Versari D, Daghini E, Virdis A, Ghiadoni L, & Taddei S (2009) Endothelial 
dysfunction as a target for prevention of cardiovascular disease.  Diabetes Care 
32 Suppl 2:S314-321. 
19. Davignon J & Ganz P (2004) Role of endothelial dysfunction in atherosclerosis.  
Circulation 109(23 Suppl 1):III27-32. 
21 
 
20. Gao YT, et al. (2007) Oxygen metabolism by endothelial nitric-oxide synthase.  J 
Biol Chem 282(39):28557-28565. 
21. Ju H, Zou R, Venema VJ, & Venema RC (1997) Direct interaction of endothelial 
nitric-oxide synthase and caveolin-1 inhibits synthase activity. J Biol Chem 
272(30):18522-18525. 
22. Panda K, Ghosh S, & Stuehr DJ (2001) Calmodulin activates intersubunit electron 
transfer in the neuronal nitric-oxide synthase dimer.  J Biol Chem 276(26):23349-
23356. 
23. Zhang Y, Janssens SP, Wingler K, Schmidt HH, & Moens AL (Modulating 
endothelial nitric oxide synthase: a new cardiovascular therapeutic strategy.  Am J 
Physiol Heart Circ Physiol 301(3):H634-646. 
24. Higashi Y, Noma K, Yoshizumi M, & Kihara Y (2009) Endothelial function and 
oxidative stress in cardiovascular diseases.  Circ J 73(3):411-418. 
25. List BM, et al. (1997) Characterization of bovine endothelial nitric oxide synthase 
as a homodimer with down-regulated uncoupled NADPH oxidase activity: 
tetrahydrobiopterin binding kinetics and role of haem in dimerization.  Biochem J 
323 ( Pt 1):159-165. 
26. Griendling KK, Sorescu D, & Ushio-Fukai M (2000) NAD(P)H oxidase: role in 
cardiovascular biology and disease.  Circ Res 86(5):494-501. 
27. Pacher P, Nivorozhkin A, & Szabo C (2006) Therapeutic effects of xanthine 
oxidase inhibitors: renaissance half a century after the discovery of allopurinol.  
Pharmacol Rev 58(1):87-114. 
22 
 
28. Cai H & Harrison DG (2000) Endothelial dysfunction in cardiovascular diseases: 
the role of oxidant stress.  Circ Res 87(10):840-844. 
29. Xia Y, Tsai AL, Berka V, & Zweier JL (1998) Superoxide generation from 
endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and 
tetrahydrobiopterin regulatory process.  J Biol Chem 273(40):25804-25808. 
30. Zweier JL, Chen CA, & Druhan LJ (S-glutathionylation reshapes our 
understanding of endothelial nitric oxide synthase uncoupling and nitric 
oxide/reactive oxygen species-mediated signaling.  Antioxid Redox Signal 
14(10):1769-1775. 
31. Boger RH, et al. (2000) An endogenous inhibitor of nitric oxide synthase 
regulates endothelial adhesiveness for monocytes.  J Am Coll Cardiol 36(7):2287-
2295. 
32. Takimoto E, et al. (2005) Oxidant stress from nitric oxide synthase-3 uncoupling 
stimulates cardiac pathologic remodeling from chronic pressure load.  J Clin 
Invest 115(5):1221-1231. 
33. Munzel T, Daiber A, Ullrich V, & Mulsch A (2005) Vascular consequences of 
endothelial nitric oxide synthase uncoupling for the activity and expression of the 
soluble guanylyl cyclase and the cGMP-dependent protein kinase.  Arterioscler 
Thromb Vasc Biol 25(8):1551-1557. 
34. Hermann M, Flammer A, & Luscher TF (2006) Nitric oxide in hypertension.  J 
Clin Hypertens (Greenwich) 8(12 Suppl 4):17-29. 
23 
 
35. Boger RH, et al. (2000) LDL cholesterol upregulates synthesis of asymmetrical 
dimethylarginine in human endothelial cells: involvement of S-
adenosylmethionine-dependent methyltransferases.  Circ Res 87(2):99-105. 
36. Matsuguma K, et al. (2006) Molecular mechanism for elevation of asymmetric 
dimethylarginine and its role for hypertension in chronic kidney disease.  J Am 
Soc Nephrol 17(8):2176-2183. 
37. Erwin PA, Lin AJ, Golan DE, & Michel T (2005) Receptor-regulated dynamic S-
nitrosylation of endothelial nitric-oxide synthase in vascular endothelial cells.  J 
Biol Chem 280(20):19888-19894. 
38. Dudzinski DM, Igarashi J, Greif D, & Michel T (2006) The regulation and 
pharmacology of endothelial nitric oxide synthase.  Annu Rev Pharmacol Toxicol 
46:235-276. 
39. Montagnani M, Chen H, Barr VA, & Quon MJ (2001) Insulin-stimulated 
activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt 
at Ser(1179). J Biol Chem 276(32):30392-30398. 
40. Fulton D, Gratton JP, & Sessa WC (2001) Post-translational control of endothelial 
nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp 
Ther 299(3):818-824. 
41. Busse R & Mulsch A (1990) Calcium-dependent nitric oxide synthesis in 
endothelial cytosol is mediated by calmodulin.  FEBS Lett 265(1-2):133-136. 
42. Dimmeler S, et al. (1999) Activation of nitric oxide synthase in endothelial cells 
by Akt-dependent phosphorylation. Nature 399(6736):601-605. 
24 
 
43. Mount PF, Kemp BE, & Power DA (2007) Regulation of endothelial and 
myocardial NO synthesis by multi-site eNOS phosphorylation.  J Mol Cell 
Cardiol 42(2):271-279. 
44. Aoyagi M, Arvai AS, Tainer JA, & Getzoff ED (2003) Structural basis for 
endothelial nitric oxide synthase binding to calmodulin.  EMBO J 22(4):766-775. 
45. Schilling K, et al. (2006) Translocation of endothelial nitric-oxide synthase 
involves a ternary complex with caveolin-1 and NOSTRIN. Mol Biol Cell 
17(9):3870-3880. 
46. Schleicher M, Brundin F, Gross S, Muller-Esterl W, & Oess S (2005) Cell cycle-
regulated inactivation of endothelial NO synthase through NOSIP-dependent 
targeting to the cytoskeleton. Mol Cell Biol 25(18):8251-8258. 
47. Zimmermann K, et al. (2002) NOSTRIN: a protein modulating nitric oxide 
release and subcellular distribution of endothelial nitric oxide synthase. Proc Natl 
Acad Sci U S A 99(26):17167-17172. 
48. Icking A, et al. (2005) NOSTRIN functions as a homotrimeric adaptor protein 
facilitating internalization of eNOS. J Cell Sci 118(Pt 21):5059-5069. 
49. Forstermann U, et al. (1994) Nitric oxide synthase isozymes. Characterization, 
purification, molecular cloning, and functions.  Hypertension 23(6 Pt 2):1121-
1131. 
50. Simon A, et al. (2003) Role of neutral amino acid transport and protein 
breakdown for substrate supply of nitric oxide synthase in human endothelial 
cells.  Circ Res 93(9):813-820. 
25 
 
51. Closs EI, Scheld JS, Sharafi M, & Forstermann U (2000) Substrate supply for 
nitric-oxide synthase in macrophages and endothelial cells: role of cationic amino 
acid transporters.  Mol Pharmacol 57(1):68-74. 
52. Santhanam L, Christianson DW, Nyhan D, & Berkowitz DE (2008) Arginase and 
vascular aging.  J Appl Physiol 105(5):1632-1642. 
53. Flam BR, Eichler DC, & Solomonson LP (2007) Endothelial nitric oxide 
production is tightly coupled to the citrulline-NO cycle.  Nitric Oxide 17(3-
4):115-121. 
54. Haines RJ, Pendleton LC, & Eichler DC (Argininosuccinate synthase: at the 
center of arginine metabolism.  Int J Biochem Mol Biol 2(1):8-23. 
55. Lockridge O, Spector EB, & Bloom AD (1977) Argininosuccinate synthetase 
activity in cultured human lymphocytes.  Biochem Genet 15(3-4):395-407. 
56. Husson A, Brasse-Lagnel C, Fairand A, Renouf S, & Lavoinne A (2003) 
Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle.  Eur 
J Biochem 270(9):1887-1899. 
57. Swamy M, Sirajudeen KN, & Chandran G (2009) Nitric oxide (NO), citrulline-
NO cycle enzymes, glutamine synthetase, and oxidative status in kainic acid-
mediated excitotoxicity in rat brain.  Drug Chem Toxicol 32(4):326-331. 
58. Goodwin BL, Solomonson LP, & Eichler DC (2004) Argininosuccinate synthase 
expression is required to maintain nitric oxide production and cell viability in 
aortic endothelial cells. J Biol Chem 279(18):18353-18360. 
59. Flam BR, Hartmann PJ, Harrell-Booth M, Solomonson LP, & Eichler DC (2001) 
Caveolar localization of arginine regeneration enzymes, argininosuccinate 
26 
 
synthase, and lyase, with endothelial nitric oxide synthase. Nitric Oxide 5(2):187-
197. 
60. Feron O, et al. (1996) Endothelial nitric oxide synthase targeting to caveolae. 
Specific interactions with caveolin isoforms in cardiac myocytes and endothelial 
cells. J Biol Chem 271(37):22810-22814. 
61. Tagawa A, et al. (2005) Assembly and trafficking of caveolar domains in the cell: 
caveolae as stable, cargo-triggered, vesicular transporters.  J Cell Biol 170(5):769-
779. 
62. Fulton D, et al. (2004) Targeting of endothelial nitric-oxide synthase to the 
cytoplasmic face of the Golgi complex or plasma membrane regulates Akt- versus 
calcium-dependent mechanisms for nitric oxide release. J Biol Chem 
279(29):30349-30357. 
63. Fulton D, et al. (2002) Localization of endothelial nitric-oxide synthase 
phosphorylated on serine 1179 and nitric oxide in Golgi and plasma membrane 
defines the existence of two pools of active enzyme.  J Biol Chem 277(6):4277-
4284. 
64. Sessa WC, et al. (1995) The Golgi association of endothelial nitric oxide synthase 
is necessary for the efficient synthesis of nitric oxide. in J Biol Chem, pp 17641-
17644. 
65. Su TS, et al. (1984) Human chromosomal assignments for 14 argininosuccinate 
synthetase pseudogenes: cloned DNAs as reagents for cytogenetic analysis.  Am J 
Hum Genet 36(5):954-964. 
27 
 
66. Gao HZ, et al. (2003) Identification of 16 novel mutations in the 
argininosuccinate synthetase gene and genotype-phenotype correlation in 38 
classical citrullinemia patients. Hum Mutat 22(1):24-34. 
67. Saheki T, et al. (2004) Adult-onset type II citrullinemia and idiopathic neonatal 
hepatitis caused by citrin deficiency: involvement of the aspartate glutamate 
carrier for urea synthesis and maintenance of the urea cycle. Mol Genet Metab 81 
Suppl 1:S20-26. 
68. Kobayashi K, Jackson MJ, Tick DB, O'Brien WE, & Beaudet AL (1990) 
Heterogeneity of mutations in argininosuccinate synthetase causing human 
citrullinemia. J Biol Chem 265(19):11361-11367. 
69. Jinno Y, Matuo S, Nomiyama H, Shimada K, & Matsuda I (1985) Novel structure 
of the 5´ end region of the human argininosuccinate synthetase gene. J Biochem 
(Tokyo) 98(5):1395-1403. 
70. Anderson GM & Freytag SO (1991) Synergistic activation of a human promoter 
in vivo by transcription factor Sp1. Mol Cell Biol 11(4):1935-1943. 
71. Guei TR, Liu MC, Yang CP, & Su TS (2008) Identification of a liver-specific 
cAMP response element in the human argininosuccinate synthetase gene.  
Biochem Biophys Res Commun 377(1):257-261. 
72. Chin AC & Fournier RE (1987) A genetic analysis of extinction: trans-regulation 
of 16 liver-specific genes in hepatoma-fibroblast hybrid cells.  Proc Natl Acad Sci 
U S A 84(6):1614-1618. 
73. Ruppert S, et al. (1990) Two genetically defined trans-acting loci coordinately 
regulate overlapping sets of liver-specific genes.  Cell 61(5):895-904. 
28 
 
74. Morris SM, Jr., et al. (1987) Regulation of mRNA levels for five urea cycle 
enzymes in rat liver by diet, cyclic AMP, and glucocorticoids.  Arch Biochem 
Biophys 256(1):343-353. 
75. Boshart M, Weih F, Nichols M, & Schutz G (1991) The tissue-specific 
extinguisher locus TSE1 encodes a regulatory subunit of cAMP-dependent 
protein kinase.  Cell 66(5):849-859. 
76. Tsai WB, et al. (2009) Resistance to arginine deiminase treatment in melanoma 
cells is associated with induced argininosuccinate synthetase expression involving 
c-Myc/HIF-1alpha/Sp4.  Mol Cancer Ther 8(12):3223-3233. 
77. Anderson HD, Rahmutula D, & Gardner DG (2004) Tumor necrosis factor-alpha 
inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic 
endothelial cells. J Biol Chem 279(2):963-969. 
78. Lai PF, Mohamed F, Monge JC, & Stewart DJ (2003) Downregulation of eNOS 
mRNA expression by TNFalpha: identification and functional characterization of 
RNA-protein interactions in the 3'UTR. Cardiovasc Res 59(1):160-168. 
79. Barsacchi R, et al. (2003) Activation of endothelial nitric-oxide synthase by 
tumor necrosis factor-alpha: a novel pathway involving sequential activation of 
neutral sphingomyelinase, phosphatidylinositol-3' kinase, and Akt. Mol 
Pharmacol 63(4):886-895. 
80. Takahashi S & Mendelsohn ME (2003) Synergistic activation of endothelial 
nitric-oxide synthase (eNOS) by HSP90 and Akt: calcium-independent eNOS 
activation involves formation of an HSP90-Akt-CaM-bound eNOS complex. J 
Biol Chem 278(33):30821-30827. 
29 
 
81. Kwon H & Pak Y (2009) Prolonged tyrosine kinase activation of insulin receptor 
by pY27-caveolin-2.  Biochem Biophys Res Commun. 
82. Goodwin B, Pendleton L, Levy M, Solomonson L, & Eichler D (2007) Tumor 
Necrosis Factor-{alpha} Reduces Substrate Availability for Nitric Oxide 
Production via Down-Regulation of Argininosuccinate Synthase. Am J Physiol 
Heart Circ Physiol 293:H1115-1121. 
83. Rothwarf DM & Karin M (1999) The NF-kappa B activation pathway: a 
paradigm in information transfer from membrane to nucleus. Sci STKE 
1999(5):RE1. 
84. Goodwin BL, et al. (2008) Troglitazone up-regulates vascular endothelial 
argininosuccinate synthase. Biochem Biophys Res Commun 370(2):254-258. 
85. Polikandriotis JA, Mazzella LJ, Rupnow HL, & Hart CM (2005) Peroxisome 
proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide 
production through distinct peroxisome proliferator-activated receptor gamma-
dependent mechanisms. Arterioscler Thromb Vasc Biol 25(9):1810-1816. 
86. Cho DH, Choi YJ, Jo SA, & Jo I (2004) Nitric oxide production and regulation of 
endothelial nitric-oxide synthase phosphorylation by prolonged treatment with 
troglitazone: evidence for involvement of peroxisome proliferator-activated 
receptor (PPAR) gamma-dependent and PPARgamma-independent signaling 
pathways. J Biol Chem 279(4):2499-2506. 
87. Fra AM, Williamson E, Simons K, & Parton RG (1995) De novo formation of 
caveolae in lymphocytes by expression of VIP21-caveolin. Proc Natl Acad Sci U 
S A 92(19):8655-8659. 
30 
 
88. Drab M, et al. (2001) Loss of caveolae, vascular dysfunction, and pulmonary 
defects in caveolin-1 gene-disrupted mice. Science 293(5539):2449-2452. 
89. Ghosh S, et al. (1998) Interaction between caveolin-1 and the reductase domain of 
endothelial nitric-oxide synthase. Consequences for catalysis. J Biol Chem 
273(35):22267-22271. 
90. Meijer HA & Thomas AA (2002) Control of eukaryotic protein synthesis by 
upstream open reading frames in the 5'-untranslated region of an mRNA. Biochem 
J 367(Pt 1):1-11. 
91. Pendleton LC, Goodwin BL, Flam BR, Solomonson LP, & Eichler DC (2002) 
Endothelial argininosuccinate synthase mRNA 5´-untranslated region diversity. 
Infrastructure for tissue-specific expression. J Biol Chem 277(28):25363-25369. 
92. Pendleton LC, Goodwin BL, Solomonson LP, & Eichler DC (2005) Regulation of 
endothelial argininosuccinate synthase expression and NO production by an 
upstream open reading frame. J Biol Chem 280(25):24252-24260. 
93. Zhao Y, et al. (2008) An NADPH sensor protein (HSCARG) down-regulates 
nitric oxide synthesis by association with argininosuccinate synthetase and is 
essential for epithelial cell viability. J Biol Chem 283(16):11004-11013. 
94. Hao G, Xie L, & Gross SS (2004) Argininosuccinate Synthetase is Reversibly 
Inactivated by S-Nitrosylation in Vitro and in Vivo. Journal of Biological 
Chemistry 279(35):36192-36200. 
95. Imami K, Sugiyama N, Kyono Y, Tomita M, & Ishihama Y (2008) Automated 
phosphoproteome analysis for cultured cancer cells by two-dimensional nanoLC-
MS using a calcined titania/C18 biphasic column.  Anal Sci 24(1):161-166. 
31 
 
96. Corbin KD, Pendleton LC, Solomonson LP, & Eichler DC (2008) 
Phosphorylation of argininosuccinate synthase by protein kinase A.  Biochem 
Biophys Res Commun 377(4):1042-1046. 
97. Mukhopadhyay S, Xu F, & Sehgal PB (2007) Aberrant cytoplasmic sequestration 
of eNOS in endothelial cells after monocrotaline, hypoxia, and senescence: live-
cell caveolar and cytoplasmic NO imaging.  Am J Physiol Heart Circ Physiol 
292(3):H1373-1389. 
98. Qian J, et al. (Role of local production of endothelium-derived nitric oxide on 
cGMP signaling and S-nitrosylation.  Am J Physiol Heart Circ Physiol 
298(1):H112-118. 
99. Kone BC, Kuncewicz T, Zhang W, & Yu ZY (2003) Protein interactions with 
nitric oxide synthases: controlling the right time, the right place, and the right 
amount of nitric oxide.  Am J Physiol Renal Physiol 285(2):F178-190. 
100. Moncada S & Higgs EA (2006) Nitric oxide and the vascular endothelium.  
Handb Exp Pharmacol (176 Pt 1):213-254. 
101. Fleming I (Molecular mechanisms underlying the activation of eNOS.  Pflugers 
Arch 459(6):793-806. 
102. Shen LJ, Beloussow K, & Shen WC (2005) Accessibility of endothelial and 
inducible nitric oxide synthase to the intracellular citrulline-arginine regeneration 
pathway. Biochem Pharmacol 69(1):97-104. 
103. Syme CA, Zhang L, & Bisello A (2006) Caveolin-1 regulates cellular trafficking 
and function of the glucagon-like Peptide 1 receptor.  Mol Endocrinol 
20(12):3400-3411.  
32 
 
 
 
 
Figure 1: Depiction of regulatory mechanisms proposed in specific aims. S328 
phosphorylation modulates caveolin and/or membrane interaction under conditions that 
affect NO production in endothelial cells. 
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PART I: REGULATION OF ARGININOSUCCINATE SYNTHASE 
PHOSPHORYLATION AT S328 RELATIVE TO ENDOTHELIAL TREATMENT 
WITH PHYSIOLOGICAL FACTORS 
 
 
Summary 
 
 Argininosuccinate synthase (AS) expression is critical for NO production in 
endothelial cells. AS catalyzes the rate-limiting step in the arginine recycling required for 
endothelial nitric oxide synthase (eNOS) substrate generation. Coordinate transcriptional 
regulation of AS and eNOS occurs in response to a number of physiological factors, 
however, little is known regarding post-translational regulation of AS. Here we identify a 
novel phosphorylation site of AS at serine 328 (S328) that responds to several endothelial 
stimuli in a coordinate fashion with eNOS S1179. Cultured bovine aortic endothelial cell 
(BAEC) treatment with calcium-independent eNOS stimulation (insulin, VEGF, and 
sodium vanadate) resulted in significant decrease in phosphorylation of AS at S328. 
Conversely, BAEC treatment with calcium-dependent activation of eNOS resulted in 
significant increase in phosphorylation of AS at S328. These results suggest that a 
function of pS328 AS is to support NO production during calcium-dependent stimulation 
of eNOS in endothelial cells. 
 
Introduction 
 Argininosuccinate synthase (AS) is a critical enzyme involved in nitric oxide 
(NO) production in the vascular endothelium (1). The expression of AS has been shown 
to increase with eNOS expression in response to troglitazone (peroxisome proliferator 
34 
 
activated receptor gamma (PPARγ) agonist) (2), insulin (3), and shear stress (4). 
Likewise, the downregulation of both AS and eNOS has been demonstrated in response 
to TNFα (5), and hypoxia (6). However, little is known relative to the regulation of AS 
beyond the level of transcription.  
 
Given the relationship with AS and NO production and the fact that NO cannot be 
stored intracellularly, a logical supposition is that AS is acutely regulated (i.e. by post-
translational modification) in order to quickly respond to the cellular demands of NO. 
Indeed, there are three known post-translational modifications: acetylation at lysine 165 
(7), nitrosylated at cysteine 132 (8), and phosphorylated at serine 352 (human sequences) 
(9), however the significance of the phosphorylation or acetylation is not known. 
Consistent with the idea that AS post-translational modification has been suggested to 
play a role in NO signaling, the S-nitrosylation of AS inhibits its activity when the 
overproduction of NO occurs (10), potentially serving as a negative feedback loop for 
NO production in endothelial cells. Furthermore, Corbin et al (11), through cultured 
bovine aortic endothelial cell (BAEC) stimulation and phospho-protein enrichment 
studies, demonstrated that phosphorylation of AS occurs in response to stimulation of NO 
production with the physiological factor vascular endothelial growth factor (VEGF). 
However, the location of the phosphorylation site was not determined at that time.  
 
In order to identify potential sites for phosphorylation, mass spectrometry was 
performed with AS purified from BAECs stimulated with factors including bradykinin 
and okadaic acid (PP1/ PP2A phosphatase inhibitor), then subsequent in silico modeling 
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studies were carried out (12) to determine relative kinase accessibility to the 
serine/threonine sites identified by mass spectrometry. Two sites, serine 180 (S180) and 
serine 189 (S189) were buried within the enzyme, and two sites threonine 131 (T131) and 
serine 328 (S328) were on the exterior of the enzyme in an area considered readily 
accessible for protein-protein interaction. Interestingly, S328 was proximal to a putative 
caveolin binding motif (ɸXXXXɸXXɸ) where ɸ is any aromatic amino acid (tryptophan, 
phenylalanine, or tyrosine) and X is any amino acid (13). Considering these data and 
observations together, we invested in the production of a phospho-specific antibody 
against phosphorylated S328 (pS328) (see experimental procedures). 
 
 To establish the potential involvement of pS328 AS in pathways relevant to 
endothelial NO production, many treatments that are known to modulate NO generation 
were utilized followed by western blotting to assess potential changes in phosphorylation. 
Stimulators and inhibitors of endothelial NO production were used to treat BAECs in a 
series of experiments. Stimulators of NO production used were: acetylcholine, 
bradykinin, Nω-hydroxy-nor-arginine (Nor-NOHA, arginase inhibitor), estradiol, sodium 
vanadate, insulin, VEGF, calcium ionophore, and lysophosphatidic acid (LPA). Inhibitors 
of NO production used included free fatty acid (FFA), homocysteine (Hcy), TNFα, and 
asymmetric dimethylarginine (ADMA) (see Table 1). Early experiments showed a 
decrease in pS328 relative to the physiological stimulators of NO production, VEGF or 
insulin. Therefore, the initial hypothesis of this study was that agents that stimulate NO 
production lead to a decrease in pS328 of AS relative to non-treated cell lysates, and 
inhibitors of NO production will lead to an increase pS328 of AS. 
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Mechanisms that stimulate endothelial NO production  
 There are several signaling pathways for activation of eNOS in endothelial cells 
including: calcium-dependent, calcium-independent (14), limiting substrate competition 
(15), or activation of upstream kinases (16). In calcium-dependent stimulation of eNOS 
(acetylcholine (17), bradykinin (17), estradiol (18), calcium ionophore), the activation of 
eNOS requires the activation of calcium dependent calmodulin (CaM) (19). Therefore, 
for calcium-dependent stimulation, an increase in the intracellular calcium concentration 
either through calcium channels in the plasma membrane or from subcellular stores in the 
endoplasmic reticulum (ER) is required. In calcium-independent stimulation of eNOS 
(insulin (20), VEGF (21), LPA (22), sodium vanadate(23)), phosphorylation events 
modulated by protein kinase B (or Akt) and phosphatases allow activated CaM present at 
basal levels to interact with eNOS (16). The increased phosphorylation of eNOS at S1179 
(via Akt activtation) and dephosphorylation at eNOS T497 (via protein phosphatase 1 
(PP1) activity) poise eNOS to be more accessible to the activated CaM that is present at 
basal levels. Therefore, the term “calcium-independent” is somewhat of a misnomer since 
activated CaM is still required for eNOS activity; however the initial event in eNOS 
activation during “calcium-independent” stimulation is not dependent on calcium. 
 
 In addition to calcium related signaling, limiting eNOS substrate competition also 
stimulates NO production (24). Endothelial cells express both cytosolic arginase I and 
mitochondrial arginase II for the catalysis of arginine to ornithine and urea (15). It has 
been established that eNOS and arginase have access to sequestered pools of arginine not 
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freely exchangeable with bulk intracellular arginine, and that inhibiting arginase with 
Nor-NOHA stimulates eNOS activity (25). Competition between eNOS and arginase 
exists because the arginase Km for arginine is in the 1-20 mM range, the eNOS Km is 
much lower at 1-5 µM (26), yet the rate of catalysis (Vmax) for arginase is 1.4 mM ˖ min
-
1˖ mg-1, while the Vmax for eNOS is 900 µM ˖ min
-1˖ mg-1(25). This indicates that arginase 
catalyzes at a faster rate, but eNOS has a higher sensitivity for arginine (27). 
Consequently, the endothelial expression of arginase I and II are considered an additional 
point of regulation for eNOS. Additionally, a functional relationship between AS and 
arginase exists in that hepatocyte AS catalyzes the rate-limiting step in urea synthesis 
when the urea cycle is saturated with substrate (28). For these reasons, the arginase 
inhibitor Nor-NOHA was used to determine whether phosphorylation at S328 of AS may 
play a role in modulating NO production when eNOS has less competition for arginine. 
 
 Upstream signaling kinases affecting eNOS activation can also be modulated in 
order to affect NO production. Sodium vanadate is a potent NO promoting agent in that it 
is a tyrosine phosphatase inhibitor, as well as tyrosine kinase activator, that has been 
shown to activate intrinsic tyrosine kinase activity of the insulin receptor (29) and 
subsequent induction of the (PI3K/ Akt pathway) of eNOS activation. In addition, 
experiments have indicated that vanadate stimulates the recruitment of HSP90, a 
chaperone that stabilizes eNOS and promotes its activity (23). Unpublished data by 
Corbin et al have demonstrated that HSP90 also associates with AS. Therefore, the 
possibility of AS phosphorylation at S328 playing a role in sodium vanadate stimulation 
of eNOS was assessed. 
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Mechanisms that prevent endothelial NO production  
 A common co-morbidity with atherosclerosis is the existence of high levels (up to 
800 µM (30)) of plasma free fatty acid (FFA). There are several ways that FFA 
negatively effects vascular health, including induction of endothelial dysfunction. 
Esenabhalu et al demonstrated that FFA impairs calcium signaling in endothelial cells 
and negatively impacts NO production (31). Therefore, endothelial cell treatment with 
FFA is a physiologically relevant means to determine whether S328 phosphorylation of 
AS is affected by disruptions in calcium mediated signaling as it relates to NO 
production.  
 
 Diabetes and metabolic syndrome are associated with elevated circulating 
inflammatory cytokines, such as TNF α, relative to healthy individuals (32). Increased 
TNF α leads to several clinical consequences associated with diabetes or metabolic 
syndrome, including endothelial dysfunction. TNF α mediates its effects on NO 
production largely by decreasing eNOS and AS expression (33), but also by decreasing 
eNOS phosphorylation at S1179 (34, 35). In addition, TNF α signaling leads to NF-κB 
activation in endothelial cells (36). NF-κB modulates transcription of genes associated 
with endothelial inflammation, such as genes associated with adhesion molecule 
expression, increasing macrophage infiltration of the vascular wall, and increased ROS 
generation (37). Therefore, TNFα was used to treat cultured endothelial cells in order to 
determine whether the phosphorylation of S328 may be involved in NF-κB signaling 
pathway, or is possibly associated with the endothelial response to inflammation.  
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 Homocysteine (Hcy) is a metabolic intermediate generated by S-
adenosylhomocysteine hydrolase in the methylation cycle. In the absence of critical co-
factors (5-methyltetrahydrofolate, co-enzyme B12 and co-enzyme B6) required for the 
conversion of Hcy to methionine, impaired Hcy renal clearance occurs and re-absorption 
into the bloodstream contributes to hyperhomocysteinemia, a condition commonly due to 
renal complications of diabetes (38). Hyperhomocysteinemia can impair endothelial 
function by inhibiting DDAH (converts asymmetric dimethylarginine (ADMA), to 
arginine, citrulline, and dimethylamine (39)) activity, thereby increasing ADMA 
production. ADMA acts as a competitive inhibitor of eNOS and contributes to superoxide 
generation by endothelial cells (40). In addition, Hcy was also shown to interfere with 
eNOS activation by increasing eNOS phosphorylation at T497 (inhibits eNOS activity) 
(41) or uncoupling eNOS (42). Therefore, endothelial treatment with Hcy or ADMA was 
used to ascertain whether S328 phosphorylation of AS plays a role in regulating eNOS 
substrate availability under mimicked conditions of hyperhomocysteinemia.  
 
  After multiple experiments with each treatment described, data were analyzed 
and trends in phosphorylation were determined relative to the type of mechanism relating 
to NO production in order to determine a potential pathway with pS328 AS involvement. 
The results of these experiments showed that mechanisms involving the PI3K/Akt eNOS 
activation pathway decreased phosphorylation of AS at S328, and mechanisms involving 
eNOS activation via calcium-dependent stimulation increased phosphorylation of AS at 
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S328. Altering arginase activity or competitive inhibition of eNOS did not significantly 
affect AS phosphorylation at S328 under these conditions. 
 
Experimental Procedures 
Cell culture 
Bovine aortic endothelial cells (BAECs) were isolated from whole bovine aorta as 
described in (43) with modifications. Aortas were harvested, washed with PBS without 
magnesium or calcium to remove blood, and lumenal surfaces were exposed by 
longitudinal dissection followed by incubation with 0.1% collagenase for 10 minutes. 
Endothelial cell isolation was achieved by rolling sterile swabs across surface, then 
releasing cells by twirling swabs in 5 ml 1 g/L glucose, 10% FBS (HyClone) enriched 
Dulbecco’s modified eagle medium (DMEM, Invitrogen) in 15 ml conical tubes.  Tubes 
were centrifuged 5 minutes at 1000 rpm at 4ºC then cells were resuspended in 6ml 
DMEM + 10% FBS and plated in 25cm
2
 treated cell culture flasks. Authentication of 
isolation of endothelial cells in culture was confirmed by flow cytometry. Cells were 
passed after they reached confluence (approximately 6 days) into treated 6 well culture 
plates. Sixteen hours before experiments, confluent cells were serum starved with 
DMEM at 1g/L glucose supplemented with 0.1% BSA and 1mM glutamine without 
phenol red.  Treatments included incubation with acetylcholine (Sigma) at 50 µM, Nor-
NOHA (EMD Chemicals) at 40 µM, sodium vanadate (Sigma) at 50 µM, estradiol at 100 
nM, LPA (Enzo Biochem) at 10 µM, FFA (Sigma; linoleic acid and oleic acid, 2 mol/mol 
albumin each) at 800 µM, TNFα (Sigma) at 10 ng/ml, ADMA (Sigma) at 100µM, insulin 
(Sigma) at 100nM, VEGF (R & D Systems) at 100ng/mL, calcium ionophore A23187 
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(Sigma) at 0.5 µM, bradykinin (Sigma) at 10 µM, incubation times are indicated in figure 
legends. Control BAECs were treated with serum starve media only. 
 
Western blot analysis 
BAEC proteins were obtained by cell lysis in RIPA buffer supplemented with 
protease and phosphatase inhibitors (Pierce) followed by scraping for collection.  Crude 
lysates were frozen at -20 ºC overnight, then vortexed at the maximum setting for 
approximately 1 minute followed by centrifugation at 4ºC at 15,000 X g for 10 minutes to 
pellet insoluble material. Protein concentration was determined with the BCA protein 
assay (Pierce) and 20ug of each lysate, as well as a dual color stained protein marker 
(Pierce) was loaded to 15 well 4-20% gradient polyacrylamide gels for SDS-PAGE (Bio-
Rad).  Gels were run at 190 V for 50 minutes followed by PVDF transfer using the semi-
dry method (Bio-Rad). Gels were placed on hydrated PVDF membranes sandwiched 
between extra-thick filter pads saturated with transfer buffer.  Sandwiches were placed in 
a semi-dry transfer unit (Bio-Rad) and ran at 17V for 36 minutes. Blots were blocked for 
1 hour followed by incubation with primary antibody (AS, eNOS, pS1179 eNOS, BD 
Transduction Laboratories; pS328 developed by 21
st
 Century Biochemicals). overnight at 
4ºC followed by two 10 minute washes in TBST.  Horseradish peroxidase (HRP) 
conjugated secondary antibody was added at 1/50,000 and incubated for 1 hour.  Blots 
were washed again then incubated with enhanced chemiluminescent substrate (Pierce) for 
5 minutes.  Blots were exposed to autoradiograph film then developed in a Kodak film 
processor. Developed films were further analyzed with a gel dock imager (Bio-rad) and 
densitometry was calculated using the basic Quantity-One software package (Bio-Rad). 
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Degree of phosphorylation was determined by dividing the densitometric value of the 
phosphorylated moiety by densitometric value of the total protein moiety and expressed 
as a percentage (i.e. (pS328 AS/ AS) *100) Change in phosphorylation relative to 
treatment was assessed by subtracting the average treated degree of phosphorylation 
determined by densitometry by average degree of phosphorylation measured in control 
lysates. Statistical comparison was performed between degree in phosphorylation of 
treated vs. non-treated for each site with the students t-test.  
 
Argininosuccinate Synthase Phosphoserine-S328 Specific antibody  
  A phospho-specific antibody against pS328 AS was developed to use for 
phospho-AS detection in western blot analysis, immunoprecipitation, and confocal 
microscopy.  The following procedure was carried out by 21st Century Biochemicals.  
The phospho-peptide corresponding the AS sequence 322-335: RR-Ahx-
YGFWH[pS]PECEFVR-amide was synthesized then purified  via high performance 
liquid chromatography followed by sequence confirmation using combined CID MS and 
QSTAR XL Pro.  The phospho-peptide was then used to immunize 2 rabbits with 4 
booster immunizations each.   
 
Three test bleeds from each animal were sent to our laboratory to ensure antigen 
specificity prior to animal sacrifice.  Specificity to the phospho-peptide sequence 
(corresponding the AS sequence 322-335: RR-Ahx-YGFWH[pS]PECEFVR-amide) was 
determined by phospho-peptide competition compared to nonphospho-peptide 
competition (corresponding the AS sequence 322-335: RR-Ahx-YGFWHSPECEFVR-
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amide).  Test bleed sera containing phospho-specific antibody was blocked with 
phospho-peptide then used to probe for phospho-AS via western blotting. Per the 
antibody and peptide manufacturing facility, a 200-fold molar excess of the peptide is 
required to effectively block antibodies for an immunoassay procedure. Therefore, either 
phospho-specific peptide or nonphospho-specific peptide was diluted to 1.334 M, and 
pS328 AS antibody was diluted to 0.0033 M with 5 ml blocking buffer (StartingBlock 
(PBS) blocking buffer, Thermo Scientific) and allowed to pre-incubate for 30 minutes. 
Blocked antibodies were then used to probe PVDF membranes with 20 µg of non-treated 
BAEC lysates in each lane (see western blotting procedure above), followed by 
secondary detection with anti-rabbit HRP and banding patterns of each lane were 
compared. Following the assessment of antigen specificity of test sera, animals were 
sacrificed and sera were affinity purified individually (i.e. not pooled) by 21st Century 
Biochemicals, Inc. The antibody was supplemented with 30% glycerol, aliquotted and 
stored at -80ºC for future use.  
 
Upon receipt of affinity purified antibody, peptide-competition experiments were 
repeated to ensure integrity and specificity of the antibody post purification. Additionally, 
BAEC lysates were immunoprecipitated and subjected to western blotting in order to 
ensure the antibody detects AS protein. Immunoprecipitation experiments were 
conducted using the Dynabeads Immunoprecipitation kit (Invitrogen) per the 
manufacturer’s instructions. The kit functions by coupling antibody via M-270 Epoxy to 
magnetic beads followed by a series of washes to remove non-specifically bound 
antibody. The advantage of coupling the antibody to the beads is that the heavy chain and 
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light chain of the antibody used to immunoprecipitate does not elute with proteins of 
interest. Non-treated BAECs were lysed with low detergent RIPA buffer (150mM NaCl, 
50mM Tris/HCl pH 7.4, 1% NP-40, 0.25% Sodium deoxycholate, 1mM EGTA, 0.1% 
Brij 35), protease and phosphatase inhibitor cocktail at 1/100 (Pierce)) and centrifuged at 
4ºC , 15, 000 rpm for 10 minutes to remove unsoluble cellular components. Six 
micrograms of each antibody (AS antibody, BD Transduction Laboratories; pS328 
developed by 21
st
 Century Biochemicals, Inc) was used to couple to beads followed by 
overnight incubation with 2 mg of BAEC lysate protein. Beads were washed 4 times with 
RIPA buffer, then proteins were eluted with elution buffer. Thirty microliters of each 
eluate was subjected to SDS-PAGE and subsequent western blotting. 
 
Nitric oxide determinations 
Nitrite measurements were assayed using the fluorescent probe 2,3-
diaminonaphthalene (DAN) (Sigma) assay as described by (44) with modifications.  
Briefly, during BAEC treatments extracellular media was collected after 15 minute 
incubation with cells at 37ºC and 5% CO2 and immediately stored at -20ºC overnight in 
tubes with limited head space. Ten milliliters of non-treated media was stored in -20ºC 
overnight to use for standard curve generation in DAN assay. A standard curve was 
generated by serially diluting 3µM sodium nitrite in media 4 times to yield concentrations 
of 2µM, 1µM, 0.5µM, and 0.25µM. Sample aliquots were thawed at room temperature 
and 100µl of each sample were added in triplicate to a 96 well plate. DAN reagent 
(33µg/ml) was prepared in 0.62 M HCl and 15µl was added to each sample and standard 
then allowed to incubate at room temperature for 15 minutes.  The reaction was stopped 
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with the addition of 30µl 2.8 M NaOH and plates were read on a BMG Fluostar Galaxy 
Spectrofluorometer with 360 nm excitation and 405 nm emission. Data are described as 
pmol nitrite per microgram protein. 
 
Results 
Anti-pS328 AS antibody is specific to target 
A phospho-specific antibody against pS328 AS was developed to use for western 
blot analysis of treated BAEC lysates. In order to ensure antibody specificity, peptide 
competition and immunoprecipitations were carried out. Since the antibody of interest 
binds to the phospho-peptide used to immunize rabbits for antibody production, 
incubating the phospho-peptide with the antibody was expected to prevent the ability of 
the antibody to detect the protein of interest in a western blot of BAEC lysates. 
Therefore, phospho-peptide (AS sequence: 322-335: RR-Ahx-YGFWH[pS]PECEFVR-
amide) block versus nonphospho-peptide (AS sequence: 322-335: RR-Ahx-
YGFWH[S]PECEFVR-amide) block of purified pS328 AS antibody was used to 
determine specificity as well as approximate molecular weight of the pS328 moiety of 
AS. Western blot analysis with the same BAEC lysates demonstrated that the antibody 
blocked by phospho-peptide showed the absence of a ~51 kDa band that was present in 
the nonphosphorylated-peptide block of the antibody (Figure 2A). In order to ensure that 
the antibody was detecting AS protein, immunoprecipitation of non-treated BAEC lysates 
using the pS328 AS antibody or commercially available monoclonal AS antibody was 
performed. Upon western blot of immunoprecipitated proteins, the monoclonal AS 
antibody detected the 48 kDa band known to be AS in lanes where total AS was 
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immunoprecipitated, and additionally detected the ~51 kDa band identified by peptide- 
competition (Figure 2B). Importantly, the monoclonal antibody against AS did not detect 
a 48 kDa band in lanes where pS328 was immunoprecipitated. These data suggest that 
the antibody is specific for pS328 AS protein at the AS sequence: 322-
YGFWH[pS]PECEFVR -335. 
 
Calcium-independent eNOS stimulation decreased AS S328 phosphorylation 
Calcium-independent induction of eNOS activity was performed with BAECs 
treated with insulin, VEGF, LPA. or sodium vanadate. Lysates were assayed for 
phosphorylation at pS1179 of eNOS as evidence of eNOS activation. Similar to previous 
reports, insulin (20) (Figure 14A) , VEGF (45) (Figure 14C), and vanadate (23) (Figure 
3A, densitometry 3B) increased phosphorylation at S1179 of eNOS. Importantly, AS 
S328 phosphorylation significantly decreased in response to treatment with insulin, 
VEGF (Figure 14), and sodium vanadate. Unexpectedly, LPA showed a decrease in 
phosphorylation at eNOS S1179 and at AS S328 (Figure 4A, densitometry 4B). To 
establish physiological relevance, culture media of treated cells was assayed for NO 
production. Consistent with reported values, NO production increased relative to insulin 
(46), VEGF (47), and sodium vanadate (23), however LPA treatment did not lead to an 
increase in NO production as previously reported (20). Collectively, these results 
suggested that phosphorylation of AS at S328 does not play a role in the endothelial 
stimulation associated with insulin, VEGF, LPA, or sodium vanadate treatment. In 
addition, these results support the idea that endothelial stimulation leads to decreased AS 
phosphorylation at S328.  
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Calcium-dependent eNOS stimulation increased AS S328 phosphorylation 
 To induce calcium-dependent eNOS stimulation, acetylcholine, estradiol, calcium 
ionophore, or bradykinin were used to treat cultured BAECs. Following treatment, cells 
were lysed and assayed for relative changes in phosphorylation of eNOS pS1179 and AS 
pS328. Since the response of eNOS phosphorylation at S1179 is known to increase 
relative to these treatments, increased phosphorylation at S1179 of eNOS served as a 
positive control. As expected, when lysates were assayed for phosphorylation at S1179 of 
eNOS, increased phosphorylation occurred in response to calcium ionophore (Figure 16), 
bradykinin (Figure 5A, densitometry 5B), and acetylcholine (Figure 6A, densitometry 
6B). However, increase in phosphorylation of eNOS at S1179 was not observed in 
response to estradiol as described (18) (Figure 7A, densitometry 7B). Contrary to the idea 
that stimulation of NO production may lead to a decrease in AS pS328, calcium-
dependent stimulation with bradykinin (Figure 5A, densitometry 5B), calcium ionophore 
(Figure 16), and acetylcholine (Figure 6A, densitometry 6B) significantly increased 
phosphorylation at S328 of AS relative to non-treated cells. In order to establish 
physiological relevance, NO measurements were taken from culture media of treated 
cells. As indicated in Figures 5C, 6C, and X, augmented NO production relative to non-
treated cells was observed for bradykinin, acetylcholine, and calcium ionophore, however 
estradiol failed to increase NO as previously reported (18) (Figure 7C).These results 
suggested that phosphorylation of AS S328 and eNOS pS1179 may be co-regulated in 
response to bradykinin, calcium ionophore, and acetylcholine.  
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Suppressed arginase activity does not affect AS S328 phosphorylation 
 Since arginase is known to play a significant role in the regulation of NO 
production by competing with eNOS for substrate (15), and AS has a functional 
relationship with arginase in the liver (1), the possibility of phosphorylation of AS at 
S328 being affected by changes in arginase activity was assessed. Experiments were 
performed to determine whether changes in phosphorylation of AS at S328 occurred in 
response to inhibited arginase activity by endothelial treatment with the synthetic 
arginine anolog Nor-NOHA. The phosphorylation state of eNOS relative to Nor-NOHA 
is not currently described, however, the degree of eNOS S1179 phosphorylation was 
determined in these experiments for consistency. As shown in Figure 8C, robust 
stimulation in NO production was observed in response to arginase inhibition with Nor-
NOHA, indicating stimulation of NO production, however change in phosphorylation of 
eNOS at S1179 relative to non-treated cells was not observed as shown in Figure 8A 
(densitometry 8B). Similarly, AS pS328 did not change in response to endothelial 
arginase inhibition (Figure 8A, densitometry 8B). These results indicate that arginase 
inhibition does not lead to regulation of eNOS at S1179 nor AS at S328.   
 
Competitive inhibition of eNOS activity does not affect AS S328 phosphoryaltion 
 Hcy acts to downregulate NO production by promoting ADMA elevation and 
eNOS uncoupling and superoxide generation in endothelial cells (42, 48). ADMA is a 
competitive inhibitor of eNOS and stimulates NADPH oxidase activity thereby serving as 
a source for superoxide generation as well. (40). Either Hcy or ADMA were used to treat 
endothelial cells in order to determine whether a relationship exists between 
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phosphorylation of AS at S328 and oxidative stress or competitive inhibition of eNOS. 
As shown in Figure 9A (densitometry 9B), phosphorylation at S1179 diminished in 
response to Hcy as described by other reports (49). Also consistent with previous studies 
(50), NO production was strongly inhibited in response to Hcy (Figure 9C). However, AS 
S328 phosphorylation did not decrease to the degree of eNOS pS1179 (Figure 9A, 
densitometry 9B). Similarly, ADMA treatment led to decreased phosphorylation at S1179 
of eNOS (Figure 10A, densitometry 10B), however decrease in S328 phosphorylation 
nearly reached significance (p<0.06, Figure 10A, densitometry 10B). BAECs responded 
physiologically to ADMA as shown by significantly reduced NO production (Figure 
10C) as previously reported. Taken together, these nearly significant changes in pS328 
shown here indicate that ADMA or Hcy treatment leading to eNOS uncoupling and/or 
increased oxidation may impact AS pS328 regulation. To resolve the precise changes in 
phosphorylation at S328 relative to superoxide generation, experiments associated with 
superoxide generation by eNOS or NADPH oxidase individually may give more insight. 
 
Calcium signaling interference via FFA decreased AS S328 phosphorylation 
 A primary mechanism involved in the FFA mediated inhibition of NO production 
involves the depletion of intra-endothelial calcium and subsequent dephosphorylation of 
eNOS (31, 51, 52). Therefore, BAECs were treated with FFA (linoleic and oleic free fatty 
acids) to ascertain the effects of altered calcium signaling on AS pS328. As shown in 
Figure 11A (densitometry 11B), significant reduction in phosphorylation of AS at S328 
and S1179 of eNOS was observed in FFA treated cells. In addition, FFA reduced NO 
production, however results were highly variable and therefore not significantly different 
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from non-treated cells (Figure 11C). These results suggest that dephosphorylation of AS 
at S328 is co-regulated with dephosphorylation of eNOS S1179 in response to FFA 
mediated signaling in endothelial cells. 
 
TNFα decreased AS S328 phosphorylation 
 Since endothelial exposure to TNFα elicits endothelial dysfunction by impairing 
eNOS phosphorylation at S1779 (34, 35),as well as increasing NF-κB activity (36), TNFα 
was used to treat BAECs to determine potential effects on AS pS328. As shown in Figure 
12A (densitometry 12B), phosphorylation of eNOS at S1179 was significantly reduced 
and NO production was inhibited (Figure 12C) as shown previously (35). In addition, AS 
S328 phosphorylation was significantly reduced in response to TNFα treatment. This 
suggests that phosphorylation at S328 is not involved in endothelial response to TNFα, 
and supports the idea that a co-regulatory relationship exists between AS pS328 and 
eNOS pS1179 under these conditions. 
 
Discussion 
In this series of experiments, we showed that AS is regulated by phosphorylation 
at S328 as the result of physiological treatment of endothelial cells with the use of a 
custom antibody directed against pS328 AS. We showed that the antibody is specific for 
the phosphorylated peptide composed of the AS sequence 322-[pS328]-335. Antibody 
specificity was determined by peptide competition with either phosphorylated [pS328] 
peptide or non-phosphorylated peptide, both peptides correlating to the AS sequence 322-
335. The competition showed that a ~51kDa band present in westerns performed with 
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non-phosphorylated 322-335 peptide blocked antibody was absent in westerns blocked 
with phosphorylated peptide 322-335. These results indicate that the detection of the 
51kDa band was inhibited when blocked with phospho-peptide, and the antibody is 
specific to pS328 because phospho-null-peptide did not effectively block detection. 
Furthermore, this 51kDa band was the only band that was blocked by pS328 peptide from 
test-bleed sera or purified antibody. Thus, the pS328 moiety of AS detected with this 
antibody runs at a molecular weight of ~51kDa. The molecular weight of AS is 
established to be ~48 kDa, approximately 3kDa smaller than the molecular weight 
observed for pS328 AS. This perceived shift in molecular weight in SDS-PAGE analysis 
often occurs due to the added phosphate group (53). In addition to peptide competition, 
we performed immunoprecipitated enrichment of pS328 AS and observed detection of a 
~51kDa band in IP eluates with commercially available monoclonal AS antibody, 
indicating that the custom antibody does indeed detect the AS protein.  
 
With an antibody that reliably detects pS328 AS, we were able to further 
characterize S328 relative to stimulation of endothelial NO production. Since our 
laboratory has shown changes in AS regulation with respect to insulin and VEGF, we 
chose these factors to observe a potential regulatory role of S328 in these pathways. The 
pathways of insulin (20), VEGF (45), and reportedly LPA (22), stimulate NO production 
in a calcium-independent manner by way of phosphoinositol three kinase (PI3K) 
activation leading to stimulation of Akt and subsequent increase in eNOS activity. 
Although LPA has been reported to function by stimulating eNOS in a calcium-
independent manner, this was not shown in these experiments. Nevertheless, the LPA 
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mechanism that impacts endothelial cells does so in a manner that decreased 
phosphorylation at eNOS at S1179 and at AS S328. Regardless of the mechanism, these 
data suggested that AS S328 and eNOS S1179 may be co-regulated under these 
conditions. 
 
With the use of established Akt dependent stimulators of eNOS, insulin and 
VEGF, we did achieve activation of eNOS evident by increased phosphorylation at 
S1179. Although we have previously reported that VEGF increased phosphorylation of 
AS (11), the phosphorylation site was not identified, therefore it is likely that AS has an 
additional phosphorylation site that responds differently to VEGF than pS328 (discussed 
in greater detail in Part II). The observation that pS328 AS decreased upon calcium-
independent activation of eNOS suggested that the kinase responsible for 
phosphorylating S328 may be inhibited under this signaling cascade. It also suggested 
that the phosphatase associated with pS328 may be up-regulated in response to insulin or 
VEGF. Since phosphatases are much fewer in number and therefore very promiscuous, 
identifying the kinase involved with S328 phosphorylation may provide more insight 
relating to the mechanism this regulatory element may be associated. Therefore, possible 
endothelial kinases that are inhibited by insulin or VEGF signaling may be responsible 
for phosphorylating AS at S328, and are worth further investigation to determine the 
function of pS328. The details of this investigation will be discussed in Part II. 
 
 Relative to calcium-dependent stimulation of eNOS, we showed that the AS S328 
is regulated in a coordinate fashion with eNOS S1179 (promotes eNOS activity) in 
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response stimulation with bradykinin, acetylcholine, and calcium ionophore. Although 
these findings showed that the increase in bradykinin stimulated S1179 phosphorylation 
was not significant, there is a strong literature base that has established that bradykinin 
promotes eNOS phosphorylation at S1179 (54, 55). With an increased sample size, it 
likely would have been shown here as well. Nevertheless, the demonstrated consistency 
by which eNOS S1179 and AS S328 phosphorylation occurs in response to acetylcholine 
and calcium ionophore coupled with the consistent decrease of only AS S328 
phosphorylation in response to insulin or VEGF suggest that a function of pS328 AS may 
be to support NO production during calcium-dependent stimulation of eNOS. 
 
 In terms of eNOS regulation, increased intracellular calcium regulates its 
dissociation with the plasma membrane caveolin, a required event in eNOS activation 
(56). Interestingly, AS has a putative caveolin binding motif (ϕXXXϕXXϕ , where ϕ 
represents an aromatic amino acid: tryptophan, phenylalanine, or tyrosine and X any 
amino acid (13)) corresponding to the AS sequence 317-FAELVYTGF-325 (Corbin et al, 
unpublished) that is proximal to S328. Therefore, phosphorylation at S328 may regulate 
interaction with caveolin. While eNOS does not have a phosphorylation site near its 
caveolin binding motif, it does have a phosphorylation site, T497, that prevents its 
association with calcium activated calmodulin, a protein-protein interaction required for 
eNOS activation (57). The regulatory role of T497 that precludes the protein: protein 
interaction with calmodulin serves as functional example for the idea that the 
phosphorylation at or near a protein interaction site may hinder interaction with its 
cognate protein. Therefore, a potential function of phosphorylation at S328 may be to 
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hinder AS association with caveolin under calcium stimulated conditions. This 
hypothesis was tested and will be described in Part III. 
 
In agreement with the observation that calcium-dependent activation of eNOS 
was associated with increased AS phosphorylation at S328, FFA, a physiological factor 
reported to diminish intracellular calcium in endothelial cells (31), showed a significant 
reduction in phosphorylation at AS S328 and eNOS 1179. In addition, endothelial 
exposure to high concentrations of FFA is associated with NF-κB activation and therefore 
up-regulates the expression of multiple genes associated with inflammation and ROS 
production, a pathway that has been identified to decrease phosphorylation of eNOS at 
S1179 (58). Therefore, the observed decrease in phosphorylation of AS at S328 and 
eNOS at S1179 may be a result of NF-κB activation as well. Further evidence for this 
conclusion was shown in this report with TNFα treatment, another factor that activates 
NFκB (35), which showed a decrease in pS328 AS and pS1179 eNOS. Therefore, the 
coordinate dephosphorylation of AS S328 and eNOS S1179 may also be associated with 
pathways leading to NFκB activation, or an effect of increased ROS generation.  
 
ROS generation also occurs by way of ADMA or Hcy treatment of endothelial 
cells (48). Multiple mechanisms exist for Hcy mediated ROS generation and eNOS 
inhibition, including increased oxidant stress, eNOS uncoupling (42), ADMA generation 
(48), inhibition of S1179 phosphorylation (49), reducing BH4 levels (50), and NF-κB 
activation (59). That being the case, it is clear how the consequences of Hcy treatment 
would decrease S1179 phosphorylation. However, the interplay between these 
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mechanisms leading to little observed change in AS S328 phosphorylation relative to Hcy 
or ADMA treatment is less clear. Although,it may also be possible that the discordant 
regulation of AS S328 and eNOS S1179 is a mechanism by which Hcy or ADMA induce 
endothelial dysfunction.  
 
Consistent with the idea that pS328 AS and pS1179 are coordinately regulated, no 
change in phosphorylation at eNOS S1179 nor AS S328 occurred in response to 
treatment with Nor-NOHA, or estradiol (results summarized in Table 2). In the case with 
Nor-NOHA treatment, limiting substrate competition for eNOS likely does not require 
additional regulation at S1179 for increased NO production. Since a basal level of 
activated eNOS occurs under non-stimulated conditions, increasing available substrate 
would result in increased NO production. The observation that regulation of AS at S328 
is also not apparent relative to Nor-NOHA treatment serves as further evidence that S328 
and S1179 are regulated in a coordinate fashion. Consistent with this reasoning, estradiol 
treatment showed no change in NO production nor phosphorylation at S1179, indicating 
that intracellular calcium was not increased by estradiol under these conditions. 
Therefore, cells were not responding to estradiol in a manner that is relevant to NO 
production. The observation that S328 phosphorylation was also not responsive to 
estradiol suggested that the pathways governing regulation at AS S328 and eNOS S1179 
were not elicited by estradiol, further supporting the idea that these sites are co-regulated. 
 
Collectively, these results suggest that pathways associated with calcium 
mediated phosphorylation of eNOS at S1179, but not calcium-independent 
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phosphorylation of eNOS, are coordinately regulated with AS S328 phosphorylation. 
Furthermore, inhibition of NO production with FFA or TNFα decreased phosphorylation 
at AS S328 and eNOS S1179, again supporting the idea that these sites are co-regulated 
under these conditions. The hypothesis that S328 phosphorylation is calcium-dependent 
will be assessed in the next section. 
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Table 1. Effect of physiological factors on eNOS activity. Agents used to establish the 
role phosphorylation of AS at S328 has in the production of NO. 
 
Agent 
Effect on NO 
Production 
Agent 
Endogenously 
Produced 
Mechanism of 
eNOS 
Regulation 
Reference 
Acetylcholine 
(Ach) 
Stimulate Yes Calcium-
dependent 
(16) 
Bradykinin 
(BK) 
Stimulate Yes Calcium-
dependent 
(16) 
Estradiol Stimulate Yes Calcium 
dependent 
(17) 
LPA Stimulate Yes Calcium-
independent 
(21) 
Insulin Stimulate Yes Calcium-
independent 
(19) 
VEGF Stimulate Yes Calcium-
independent 
(20) 
Nor-NOHA Stimulate No Inhibits 
arginase 
(24) 
Na Vanadate  Stimulate Trace levels Calcium-
independent 
(22) 
Free Fatty 
Acid (FFA) 
Inhibit Yes Alters calcium (30) 
TNFα Inhibit Yes Downregulates 
eNOS 
expression 
(33, 34) 
ADMA Inhibit Yes eNOS 
competitive 
inhibitor 
(39) 
Homocysteine 
(Hcy) 
Inhibit Yes Uncouples 
eNOS, 
    ADMA 
(38,41) 
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Table 2. Summary of Changes in eNOS and AS Phosphorylation Relative to Treatment. 
The observed effects on eNOS phosphorylation at S1179 and AS phosphorylation at 
S328 relative to different mechanisms of NO stimulation. Bolded items represent a 
common change in phosphorylation between eNOS S1179 and AS S328. 
 
Treatment 
Known 
effect on 
NO 
production 
Mechanism of 
eNOS regulation 
Observed effect 
on pS1179 
eNOS 
Observed effect 
on pS328 AS 
Acetylcholine 
(Ach) 
Stimulate Calcium-
dependent 
Increase Increase 
Bradykinin 
(BK) 
Stimulate Calcium-
dependent 
Increase Increase 
Estradiol Stimulate Calcium 
dependent 
No change No change 
LPA Stimulate Calcium-
independent 
Decrease Decrease 
Insulin Stimulate Calcium-
independent 
Increase Decrease 
VEGF Stimulate Calcium-
independent 
Increase  Decrease 
Nor-NOHA Stimulate Inhibits 
arginase 
No change No change 
Na Vanadate  Stimulate Calcium-
independent 
Slight 
increase 
Decrease 
Free Fatty 
Acid (FFA) 
Inhibit Alters calcium Decrease Decrease 
TNFα Inhibit Downregulates 
eNOS 
expression 
Decrease Decrease 
ADMA Inhibit eNOS 
competitive 
inhibitor 
Decrease 
(slight) 
Decrease 
(slight) 
Homocysteine 
(Hcy) 
Inhibit Uncouples 
eNOS, 
    ADMA 
Decrease No change 
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Figure 2: Custom antibody is specific to pS328 AS. Rabbits were immunized with AS 
sequence 322-335: RR-Ahx-YGFWH[pS]PECEFVR-amide then sacrificed. Antibody 
was purified by affinity chromatography then analyzed for specificity. (A) BAEC lysates 
were subjected to SDS-PAGE then transferred to PVDF. Lanes were cut into strips then 
incubated with antibody without peptide (left lane),with  non-phosphorylated peptide 
(middle lane), or with phospho-peptide (right lane). Blots are representative of 4 
experiments. (B) Non-treated BAEC lysates were immunoprecipated (IP) with either 
anti-V5 tag (Lane 1; negative control), commercially available AS antibody (Lanes 2 and 
3), or custom anti-pS328 antibody (Lanes 4 and 5) then IP eluates were analyzed by 
western blot with monoclonal anti-AS immunodetection. Bottom blot represents lighter 
exposure of the upper blot. Blot is representative of 5 experiments. 
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Figure 3. Sodium vanadate treatment of BAECs showed decreased phosphorylation of 
AS at S328 and increased phosphorylation of eNOS at S1179.  BAECs were serum 
starved 16 hours then treated with sodium vanadate or serum starve media alone for 1 
hour. (A) Western showing relative change in phosphorylation of AS at S328 and eNOS 
at S1179. (B) Quantitation of densitometry represents the change in AS S328 and eNOS 
S1179 phosphorylation of treated lysates relative phosphorylation present in non-treated 
lysates. GAPDH expression was used as loading control. Changes in phosphorylation are 
statistically significant (n=4, *p<0.05). (C) DAN assay for NO production in extracellular 
culture media of vanadate stimulated cells showed a statistically significant increase in 
NO production relative to non-treated cells. 
 
 
 
 
* 
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Figure 4. LPA treatment of BAECs showed decreased phosphorylation of AS at S328 and  
eNOS at S1179.  BAECs were serum starved 16 hours then treated with LPA or serum 
starve media alone for 1 hour. (A) Western showing relative change in phosphorylation 
of AS at S328 and eNOS at S1179. (B) Quantitation of densitometry represents the 
change in AS S328 and eNOS S1179 phosphorylation of treated lysates relative 
phosphorylation present in non-treated lysates, n=2. GAPDH expression was used as 
loading control (not shown). Changes are not considered statistically significant because 
of the small sample size. (C) DAN assay for NO production in extracellular culture media 
of treated and non-treated cells showed that there is not a significant difference in NO 
production between treated and non-treated cells. 
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Figure 5. Bradykinin (BK) treatment of BAECs showed increased phosphorylation of AS 
at S328 and eNOS at S1179.  BAECs were serum starved 16 hours then treated with BK 
or serum starve media alone for 30 minutes. (A) Western showing relative change in 
phosphorylation of AS at S328 and eNOS at S1179. (B) Quantitation of densitometry 
represents the change in AS S328 and eNOS S1179 phosphorylation of treated lysates 
relative phosphorylation present in non-treated lysates, n=4. GAPDH expression was 
used as loading control (not shown). Change in phosphorylation of pS328 was significant 
(* p<0.05). Change in S1179 phosphorylation did not reach significance (p<0.07) (C) 
DAN assay for NO production in extracellular culture media of treated and non-treated 
cells showed significant (n=4, *p<0.05) increase in NO production as the result of BK 
treatment. 
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Figure 6. Acetylcholine (Ach) treatment of BAECs showed increased phosphorylation of 
AS at S328 and eNOS at S1179.  BAECs were serum starved 16 hours then treated with 
Ach or serum starve media alone for 1 hour. (A) Western showing relative change in 
phosphorylation of AS at S328 and eNOS at S1179. (B) Quantitation of densitometry 
represents the change in AS S328 and eNOS S1179 phosphorylation of treated lysates 
relative phosphorylation present in non-treated lysates, n=4. GAPDH expression was 
used as loading control (not shown). Changes are not considered statistically significant 
because of high variability. (C) DAN assay for NO production in extracellular culture 
media showed statistically significant (n=4, * p<0.05) increase in NO production by 
treated cells relative to non-treated. 
 
 
 
 
71 
 
 
Figure 7. Estradiol treatment of BAECs showed no change in phosphorylation of AS at 
S328 or eNOS at S1179.  BAECs were serum starved 16 hours then treated with estradiol 
or serum starve media alone for 1 hour. (A) Western showing relative change in 
phosphorylation of AS at S328 and eNOS at S1179. (B) Quantitation of densitometry 
represents the change in AS S328 and eNOS S1179 phosphorylation of treated lysates 
relative phosphorylation present in non-treated lysates, n=2. GAPDH expression was 
used as loading control (not shown). Changes are not statistically significant. (C) DAN 
assay for NO production in extracellular culture media of treated and non-treated cells 
showed no change between the two groups. 
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Figure 8. Arginase inhibition with Nor-NOHA treatment of BAECs showed no change in 
phosphorylation of AS at S328 or eNOS at S1179.  BAECs were serum starved 16 hours 
then treated with Nor-NOHA or serum starve media alone for 1 hour. (A) Western 
showing relative change in phosphorylation of AS at S328 and eNOS at S1179. (B) 
Quantitation of densitometry represents the change in AS S328 and eNOS S1179 
phosphorylation of treated lysates relative phosphorylation present in non-treated lysates, 
n=2. GAPDH expression was used as loading control (not shown). Changes are not 
considered statistically significant because of the small sample size. (C) DAN assay for 
NO production in extracellular culture media showed increased NO production in treated 
cells relative to non-treated cells. 
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Figure 9. Homocysteine (Hcy) treatment of BAECs showed a slight decrease in 
phosphorylation of AS at S328 and stronger decrease in phosphorylation of eNOS at 
S1179.  BAECs were serum starved 16 hours then treated with Hcy or serum starve 
media alone for 1 hour. (A) Western showing relative change in phosphorylation of AS at 
S328 and eNOS at S1179. (B) Quantitation of densitometry represents the change in AS 
S328 and eNOS S1179 phosphorylation of treated lysates relative phosphorylation 
present in non-treated lysates, n=2. GAPDH expression was used as loading control (not 
shown). Changes are not considered statistically significant because of the small sample 
size. (C) DAN assay for NO production in extracellular culture media showed decreased 
NO production by Hcy treated cells relative to non-treated. 
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Figure 10. Asymmetric dimethylarginine (ADMA) treatment of BAECs showed 
decreased phosphorylation of AS at S328 and  eNOS at S1179.  BAECs were serum 
starved 16 hours then treated with ADMA or serum starve media alone for 1 hour. (A) 
Western showing relative change in phosphorylation of AS at S328 and eNOS at S1179. 
(B) Quantitation of densitometry represents the change in AS S328 and eNOS S1179 
phosphorylation of treated lysates relative phosphorylation present in non-treated lysates, 
n=3. GAPDH expression was used as loading control (not shown). Change in 
phosphorylation of pS328 was near statistical significance (p<0.06). Change in S1179 
phosphorylation was significant (n=3, * p<0.05) (C) DAN assay for NO production in 
extracellular culture media showed a statistically significant decrease (n=3, * p<0.05 in 
NO production in treated cells relative to non-treated cells. 
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Figure 11. Free fatty acid (FFA) treatment of BAECs showed decreased phosphorylation 
of AS at S328 and  eNOS at S1179.  BAECs were serum starved 16 hours then treated 
with FFA or serum starve media alone for 1 hour. (A) Western showing relative change 
in phosphorylation of AS at S328 and eNOS at S1179. (B) Quantitation of densitometry 
represents the change in AS S328 and eNOS S1179 phosphorylation of treated lysates 
relative phosphorylation present in non-treated lysates, n=5. GAPDH expression was 
used as loading control (not shown). Changes in phosphorylation were significant (n=5, 
*p<0.05) (C) DAN assay for NO production in extracellular culture media showed a 
decrease in NO production in treated cells relative to non-treated cells, although the 
change was not considered significant because of high variability.  
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Figure 12. TNFα treatment of BAECs showed decreased phosphorylation of AS at S328 
and eNOS at S1179.  BAECs were serum starved 16 hours then treated with TNFα or 
serum starve media alone for 1 hour. (A) Western showing relative change in 
phosphorylation of AS at S328 and eNOS at S1179. (B) Quantitation of densitometry 
represents the change in AS S328 and eNOS S1179 phosphorylation of treated lysates 
relative phosphorylation present in non-treated lysates, n=3. GAPDH expression was 
used as loading control (not shown). Changes in phosphorylation were significant (n=3, * 
p<0.05) (C) DAN assay for NO production in extracellular culture media showed a 
decrease in NO production in treated cells relative to non-treated cells, although high 
variability prevented statistical significance. 
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PART II: PKCα PHOSPHORYLATES A NOVEL ARGININOSUCCINATE 
SYNTHASE SITE AT S328 DURING CALCIUM-DEPENDENT STIMULATION 
OF ENDOTHELIAL NITRIC OXIDE SYNTHASE IN VASCULAR 
ENDOTHELIAL CELLS
1
 
 
 
 
Summary 
 
Endothelial nitric oxide synthase (eNOS) utilizes L-arginine as its principal 
substrate, converting it to L-citrulline and NO. L-citrulline is recycled to L-arginine by 
two enzymes, argininosuccinate synthase (AS) and argininosuccinate lyase (AL), 
providing the substrate arginine for eNOS and NO production in endothelial cells. 
Together, these three enzymes, eNOS, AS and AL, make up the citrulline-NO cycle. 
Although AS catalyzes the rate-limiting step in NO production, little is known about the 
regulation of AS in endothelial cells beyond the level of transcription. In this report, we 
showed that AS S328 phosphorylation was coordinately regulated with eNOS S1179 
phosphorylation when bovine aortic endothelial cells (BAECs) were stimulated by either 
a calcium ionophore or thapsigargin to produce NO. Furthermore, using in vitro kinase 
assay, kinase inhibition studies, as well as PKCα knockdown experiments, we 
demonstrate that the calcium-dependent phosphorylation of AS S328 is mediated by 
PKCα. Collectively, these findings suggest that phosphorylation of AS at S328 is 
regulated in accordance with the calcium-dependent regulation of eNOS under conditions 
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that promote NO production, and are in keeping with the rate-limiting role of AS in the 
citrulline-NO cycle of vascular endothelial cells. 
 
Introduction  
Nitric oxide (NO) production is strictly regulated in vascular endothelial cells. 
Impairment of this control is associated with risk factors that compromise endothelial 
function. Arginine directed to eNOS for purposes of NO production is maintained by the 
recycling of citrulline to arginine, creating a distinct pool of arginine in endothelial cells 
(1-4). This intracellular arginine pool that is sequestered from the bulk cytosolic arginine 
is generated through the action of the arginine recycling enzymes argininosuccinate 
synthase (AS) and argininosuccinate lyase (AL), where catalysis by AS is rate-limiting 
for NO production in endothelial cells (5).  
 
Since the endothelium represents a unique environment under the continuous 
influence of signaling cascades that integrate responses to physiologic cues, it was logical 
to propose that acute or immediate regulation of AS would be necessary to accommodate 
regulatory responses already known for eNOS. For example, VEGF and insulin signaling 
have been shown to coordinately regulate two phosphorylation sites of eNOS, increasing 
phosphorylation at S1179 and decreasing phosphorylation at T497 to affect an overall 
increase in eNOS activity (6). This change in eNOS phosphorylation that results from 
either VEGF or insulin signaling is mediated largely by calcium-independent kinases, 
such as Akt (7).  
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Despite the fact that relatively recent reports have shown that AS is a 
phosphophoprotein (8, 9), no physiologically relevant phosphorylation sites have been 
reported. In 2008, an automated phosphoproteome analysis revealed that AS is 
phosphorylated at serine 352 in HeLa cells, but the physiologic significance was not 
established (9). Later that same year, Corbin et al also demonstrated that AS was a 
phosphoprotein, and that VEGF stimulation of NO production affected the 
phosphorylation of AS via a PKA pathway, but no phosphorylation site was identified 
(8). In this report, we now show that phosphorylation of AS at serine 328 (S328) occurs 
in response to the calcium-dependent activation of eNOS, and is mediated by PKCα.  
 
Experimental Procedures 
Cell culture 
BAECs were isolated from whole bovine aorta as described in (10) with 
modifications. Briefly, aortas were harvested, washed with PBS without magnesium or 
calcium to remove blood, and lumenal surfaces were exposed by longitudinal dissection 
followed by incubation with 0.1% collagenase for 10 minutes. Endothelial cell isolation 
was achieved by rolling sterile swabs across surface, then releasing cells by twirling 
swabs in 5ml enriched Dulbecco’s modified eagle medium (DMEM, 1g/L glucose, 
Invitrogen) containing 10% FBS (HyClone) with 100 IU/ml penicillin and streptomycin 
and 250 ng/ml amphotericin B (Cellgro) in 15 ml conical tubes. Cells were pelleted, 
resuspended in 6ml DMEM + 10% FBS and plated in 25cm
2
 treated cell culture flasks. 
Authentication of isolation of endothelial cells in culture was confirmed by flow 
cytometry.  
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Prior to treatment confluent BAEC (between passage 3 and 9) were serum starved 
for 16 hours in DMEM (1g/L glucose, minus phenol red, Invitrogen) supplemented with 
0.1% BSA and 1mM glutamine. Treatments included incubation with 100nM insulin 
(Sigma), 100ng/ml VEGF (R & D Systems), 0.5µM calcium ionophore A23187 (Sigma), 
10µM bradykinin (Sigma), 42µM rottlerin or 2.5µM bisindolylmaleimide I (Sigma) for 
PKC inhibition, or 50µM BAPTA (Calbiochem). Incubation times are indicated in figure 
legends. Controls were treated with serum starve media only 
 
Generation of AS variants and transient transfections 
AS cDNA was subcloned into pcDNA 3.1/ V5-His, B expression vector 
(Invitrogen). The AS consruct was then subjected to site directed mutagenesis via the 
QuikChange kit (Stratagene) per manufacturer’s instructions. Briefly, S328 was mutated 
to alanine (A) to mimic a non-phosphorylated state and to aspartic acid (D) to mimic a 
constitutively phosphorylated state. Primers used for S328A mutation were sense: 
ACGGGTTTCTGGCACGCGCCCGAGTGTGAATTT and antisense: 
AAATTCACACTCGGGCGCGTGCCAGAAACCCGT. Primers used for S328D 
mutation were sense: ACGGGTTTCTGGCACGACCCCGAGTGTGAATTT and 
antisense: AAATTCACACTCGGGGTCGTGCCAGAAACCCGT. Experimental 
plasmids (1 μg DNA/well of a 6 well dish) were transiently transfected into BAEC using 
Lipofectamine 2000 (Invitrogen) in serum free Opti-MEM I (Invitrogen). After 4 h, 
media was replaced with DMEM containing 10% serum and cells were cultured for 6 or 
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24 h. Cells were stimulated with calcium ionophore A23187 and sodium orthovanadate 
for 4 hours then culture media was assayed for NO production via the DAN assay. 
 
Mass spectrometry analysis 
BAEC transiently transfected with AS were incubated 24 hours, serum starved for 
16 hours, and treated with 10µM bradykinin or 50nM okadaic acid for 30 minutes. 
Overexpressed AS was purified by its fused 6X-His tag using Ni-NTA agarose magnetic 
beads (Qiagen). Proteins were separated by SDS-PAGE to identify the AS band (51 kD). 
A duplicate gel was run to confirm expression of the AS plasmid by western blot. Gel 
bands of interest were excised and destained. The protein disufides were reduced with 
triscarboxyethylphosphine and the cysteines were alkylated with iodoacetamide. In-gel 
trypsin digestion was used for proteolysis. Nanoflow reverse phase liquid 
chromatography was used to separate the peptides by hydrophobicity (LC Packings, 
Dionex, Sunnyvale, CA). Online detection was accomplished with an electrospray linear 
ion trap mass spectrometer (LTQ, Thermo, San Jose, CA). Tandem mass spectra were 
assigned to peptide sequences using Mascot and Sequest database search algorithms. 
Sequence assignments were validated by manual inspection of the data. 
 
Argininosuccinate synthase phosphoserine S328 specific antibody 
A phospho-specific antibody against pS328 AS was generated by 21st Century 
Biochemicals using the phospho-peptide AS sequence 322-335: RR-Ahx-
YGFWH[pS]PECEFVR-amide. The phospho-AS antibody specificity was determined by 
performing phospho-peptide competition of immunoprecipitations and western blotting. 
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Western blot analysis 
BAEC were lysed in RIPA buffer supplemented with protease and phosphatase 
inhibitors (Pierce) followed by scraping for collection. Whole cell lysates were clarified 
and total protein was quantitated using the BCA protein assay (Pierce). Equal amounts 
(20µg) of protein were resolved on 4-15% Tris-HCl TGX precast gels (Bio-Rad) and 
blotted onto Immobilon-P polyvinylidene difluoride membranes. Western blotting was 
performed as previously described (11). Membranes were blocked in 100% Starting 
Block (Pierce) and incubated with primary antibody, 1:2500 anti-AS (BD Transduction 
Labs), in 20% Starting Block. Secondary antibody used was peroxidase-conjugated goat 
anti-mouse or anti-rabbit IgG (Jackson ImmunoResearch Labs) at 1:50,000 dilution. 
Blots were visualized by chemiluminescence using West Pico reagent (Pierce) and 
exposed to film. Band intensities were quantitated using Quantity-One software (Bio-
Rad).  
 
Nitric oxide determination 
Nitrite was measured in the medium as an indicator of cellular NO using the 
fluorescent 2,3-diaminonaphthalene (DAN) (Sigma) assay as described previously (12). 
Reactions were carried out in 96 well black plates and fluorescence was read on a BMG 
FLUOstar Galaxy spectrofluorometer platereader exciting at 360nm and detecting 
emission at 405nm. Data are described as pmol nitrite per microgram protein. 
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PKCα knockdown assay 
BAEC, 90% confluent, were transfected for 48 hours with DsiRNA (dicer-
substrate siRNA) directed against the 5
th
 exon of PKCα (IDT) using lipofectamine 2000 
(Invitrogen) performed as described previously for AS constructs. The duplex sequence 
used to silence the gene expression was the following: 5'-rCrGrA rGrGrA rGrCrA 
rArGrC rArCrA rArGrU rUrCrA rArGA T-3' 5'-rArUrC rUrUrG rArArC rUrUrG 
rUrGrC rUrUrG rCrUrC rCrUrC rGrGrG-3'. Transfected BAEC were then treated with 
calcium ionophore (A23187, Sigma) and lysed followed by western blotting. Relative 
amounts of indicated proteins were quantitated as described above. 
 
In vitro kinase assay 
Assays were performed as described by Corbin et al. (8). Breifly, purified 
recombinant AS was generated via subcloning bovine AS (NP_776317) into the pET-
28(c)+ vector (Novagen) and expressed in E. coli. The protein was subsequently purified 
via the His-bind resin per the manufacturer’s instructions (Novagen). Successful 
purification was verified by SDS-PAGE. The positive control used to determine kinase 
activity for each kinase contained applicable peptide substrate, while negative control 
contained all components except peptide. Addition of 
33
P-ATP to each reaction mixture 
initiated the assays incubated at 30ºC for 30 minutes. Assay termination was achieved by 
reaction spotting on phosphocellulose P81 plates followed by 3 washes then radioactivity 
read via scintillation counting. Imaged in vitro kinase reactions were terminated by 
addition of sample buffer then fractionated on 10% polyacrylamide gels.  
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Results 
Identification of the argininosuccinate synthase S328 phosphorylation site  
In order to establish biologically significant sites of phosphorylation in the AS 
sequence, we carried out a proteomic analyses by applying mass spectrometry (LC-
MS/MS) on overexpressed AS purified from cultured BAECs treated with bradykinin or 
okadaic acid (PP2A and PP1 phosphatase inhibitor). Mass spectrometry analysis revealed 
three highly conserved serine/threonine phosphorylation sites that were distinguished 
from background ion signal. These included threonine 131 (T131)/ serine 134 (S134), 
serine 180 (S180)/ serine 189 (S189), and serine 328 (S328) (Figure 1). The proximity of 
T131 to S134 and S180 to S189 made these individual signals indistinguishable and 
therefore described as T131/S134 and S180/S189.  
 
Of the sites identified, S328 showed the greatest change in signal between cells 
treated with phosphatase inhibitor (okadaic acid) and non-treated cells. In addition, S328 
showed substantial change in signal with bradykinin treatment relative to non-treated 
control cells (Figure 13). Furthermore, in silico modeling showed that the most accessible 
sites for kinase interaction were T131/S134 and S328 while S180/S189 appeared buried 
near the active site of the enzyme (Data not shown). Based on these results, S328 was 
selected as being the strongest candidate for phosphorylation in vivo. Consequently, a 
phospho-specific antibody directed against pS328 was developed for further investigation 
(see EXPERIMENTAL PROCEDURES).  
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Calcium-independent stimulation of BAECs decreases phosphorylation at S328  
To determine whether phosphorylation at S328 had physiological significance, 
changes in S328 phosphorylation were examined relative to treatment by physiological 
cues that alter NO production. In particular, VEGF and insulin stimulation of NO 
production were chosen for two reasons. First, there is evidence that AS phosphorylation 
changed in response to VEGF treatment which was mediated via PKA signaling. (8). 
Second, both VEGF and insulin are known to stimulate endothelial NO production by 
promoting phosphorylation of S1179 of eNOS (13, 14). 
 
As shown in Figure 14, and consistent with the literature (13), we found that 
insulin and VEGF promoted an increase in phosphorylation by roughly 50% of eNOS at 
S1179 (western Figure 14A,C; densitometry Figure 14B,D), with a corresponding 
increase in NO production (Figure 14E). There was also concomitant decrease in 
phosphorylation of eNOS at T497 by approximately 40% (western Figure 14A,C; 
densitometry Figure 14B,D) (15-17). Surprisingly, phosphorylation at S328 was 
markedly reduced by treatment with either VEGF (85%) or insulin (40%) (western Figure 
14A,C; densitometry Figure 14B,D). 
 
Calcium-dependent stimulation of BAECs increases phosphorylation at S328  
Insulin and VEGF mediate eNOS phosphorylation at S1179 via the PI3K/Akt 
pathway which is largely calcium-independent (18-20). Since calcium-independent 
signaling mediated by either insulin or VEGF promoted the apparent dephosphorylation 
of AS S328, we then questioned whether phosphorylation at S328 was involved with 
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calcium-dependent signaling. To initially explore this question, site-directed mutagenesis 
analysis was carried out. Three constructs were used, one containing wild type AS, one 
containing an alanine substitution for S328 (phospho-null), and one containing an 
aspartate substitution for S328 (phospho-mimetic). As shown in Figure 15A, the 
overexpression of the phospho-mimetic S328D AS or wild type AS (WT) led to a two-
fold increase in NO production relative to overexpressed S328A when stimulated with 
calcium ionophore and sodium orthovanadate. Consistent expression of the constructs is 
shown by western blotting (Figure 15B). The observation that WT and S328D gave a 
similar response in NO production may imply that WT is phosphorylated endogenously 
at S328 in response to this treatment as well. 
 
Since these findings were consistent with a calcium-dependency, experiments 
were then carried out to determine whether calcium-dependent changes in S328 could be 
demonstrated for endogenous AS. For these experiments, BAECs were treated with either 
the calcium ionophore, A23187, or the endoplasmic reticulum ATPase inhibitor, 
thapsigargin. Both agents are known to promote an intracellular increase in calcium (21) 
and stimulate NO production. As shown in Figures 4A and 4B, treatment with either 
agent promoted phosphorylation of eNOS at S1179 by nearly 50% with a subsequent 
decrease in phosphorylation of eNOS at T497 by 40%, consistent with reported values 
(21, 22). However, in this case, treatment with calcium ionophore or thapsigargin 
demonstrated an increase in phosphorylation at AS S328 (~60%) (Figure 16A,B). 
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To further substantiate the calcium dependency of AS S328 phosphorylation, 
BAECs were treated with the intracellular calcium chelator BAPTA-AM. As expected, 
calcium ionophore and thapsigargin rescued phosphorylation at eNOS pS1179 that 
diminished with BAPTA-AM treatment alone. Importantly, as shown in Figure 16A, 
treatment with 50 µM BAPTA-AM completely abolished phosphorylation at S328, as 
well as the phosphorylation at eNOS S1179. Thus, phosphorylation of AS S328 appeared 
to be coordinately regulated with the phosphorylation of eNOS S1179 through calcium-
dependent signaling. 
  
To demonstrate physiological relevance, NO measurements were taken after cells 
were treated with BAPTA-AM for 30 minutes followed by stimulation with calcium 
ionophore A23187 for 20 minutes. A23187 and thapsigargin significantly increased NO 
production relative to non-treated or BAPTA-AM treated BAECs (Figure 16C). In 
addition, BAPTA-AM treatment significantly decreased A23187 or thapsigargin 
stimulated NO production by 2.5 and 2-fold respectively.  
 
PKC is involved in mediating S328 phosphorylation in BAECs  
In order to further elucidate the signaling pathway involved in the calcium-
dependent phosphorylation of AS at S328, a series of experiments were carried out using 
kinase inhibitors. Since the classical protein kinase C (PKC) isotypes are calcium-
dependent kinases and are not involved in insulin or VEGF signaling (23, 24), we 
hypothesized that a member of the PKC family may be involved in the calcium-
dependent phosphorylation of AS S328. To test this hypothesis, non-isotype specific 
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PKC inhibition studies were carried out. As a first approach, the effects of PKC inhibition 
were directly measured by examining AS S328 phosphorylation. As shown in Figure 17A 
and B, treatment of BAECs with either the PKC inhibitor rottlerin or bisindolylmaleimide 
I, followed by stimulation with calcium ionophore, decreased AS S328 phosphorylation 
by approximately 60% relative to non-treated controls. These results were taken to be 
consistent and supportive of the role of a classical PKC isotype promoting 
phosphorylation of AS at S328.  
 
Interestingly, phosphorylation at T497 or S1179 of eNOS also decreased with 
treatment of rottlerin by approximately 60%, irrespective of calcium stimulation. In 
contrast, when BAECS were treated with bisindolylmaleimide I alone, phosphorylation at 
S1179 and T497 of eNOS decreased by only 20%. However, upon calcium stimulation, 
phosphorylation at eNOS S1179 increased to levels similar to calcium ionophore 
treatment alone. Nevertheless, phosphorylation at S328 was unaffected by calcium in 
presence of bisindolylmaleimide I (Figure 17A).  
 
In order to demonstrate physiological relevance of the system in response to 
inhibitors, we measured NO production for each treatment (Figure 17C). PKC inhibition 
with bisindolylmaleimide I has little effect on NO production by BAECs, however 
rottlerin significantly reduced calcium ionophore stimulated NO production by over 2-
fold. These results suggest that rottlerin may affect the activity of several kinases, and 
bisindolylmaleimide I clearly decreased phosphorylation at eNOS T497 and thus 
promoted NO production similar to calcium ionophore alone.  
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To further examine the potential involvement of other calcium-dependent kinases 
that could phosphorylate S328, additional kinase inhibition studies were carried out. 
ERK1/2 was inhibited with PD 98059 and CaMKII was inhibited with KN93. In either 
case, no inhibitor effect was observed on AS S328 phosphorylation when BAECs were 
co-treated with calcium ionophore or thapsigargin (data not shown). These results suggest 
that PKC, but not ERK1/2 or CaMKII, is responsible for the calcium stimulated 
phosphorylation of AS S328.  
 
Since the α isotype of PKC (PKCα) is a calcium-dependent kinase that has been 
shown to be active during calcium-dependent stimulation of eNOS (25), we sought to 
determine whether this is the isotype responsible for phosphorylating S328 of AS. To test 
this, we examined the effects of direct knockdown of PKCα with dicer substrate siRNA 
(DsiRNA). DsiRNA is different from traditional siRNA used for gene silencing in that 
the RNA duplex used to silence not only mimics dicer products, but is also optimized for 
dicer processing by the RISC complex to result in a more potent knockdown (26). As 
shown in Figure 18, significant knockdown of PKCα was achieved. DsiRNA directed 
against PKCα allowed for 50% and 75% knockdown at 1nM and 5nM DsiRNA, 
respectively. Knockdown of PKCα followed by treatment with calcium ionophore 
showed a decrease in phosphorylation of S328 by 50% and 60% with 1nM or 5nM, 
respectively, and prevented increased phosphorylation in response to calcium ionophore 
treatment. Phosphorylation of eNOS at S1179 was largely unaffected by PKCα 
knockdown under these conditions, while eNOS T497 dropped approximately 60% when 
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PKCα was knocked down by 80%. These results suggest that PKCα is a kinase that 
phosphorylates S328 of AS.  
 
PKCα directly phosphorylates AS 
Since an observed decrease in phosphorylation due to kinase knockdown may be 
the result of inhibition of an upstream kinase in a signaling cascade, a targeted in vitro 
kinase assay was performed to determine whether PKCα directly phosphorylates AS. 
Akt1 was used as a negative control based on the lack of a consensus Akt 
phosphorylation motif (R-X-R-X-X-S/T) (27) in the AS protein sequence.  
 
As shown in Figure 19A, PKCα clearly demonstrated the capacity to 
phosphorylate AS in vitro. Although there was an increase in counts above the blank 
reaction with Akt1, this was below the threshold considered significant. SDS-PAGE 
fractionation of [
32
P]-labeled kinase reaction products and visualization by 
autoradiography film exposure confirmed that PKCα, but not Akt1, phosphorylates AS 
(Figure 19B).  
 
Discussion 
NO production is a dynamic and targeted process, and multi-level regulation of 
eNOS is well established (28) to control this process. Since AS is required for NO 
production, it was logical to speculate that post-translational regulation of AS would play 
a significant role in maintaining NO homeostasis. Indeed, recent work using mass 
spectrometry analysis has shown that AS is phosphorylated at site S352 (human 
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sequence) (9); however, the biological significance of the phosphorylation at serine 352 
was not defined. In addition, Corbin et al (8) showed that phosphorylation of AS was 
changed in response to VEGF treatment, nevertheless the phosphorylation site was 
unknown. In this report, we demonstrate that AS S328 phosphorylation relates to the 
calcium-dependent stimulation of NO production, and is mediated by PKCα (see working 
model, Figure 20).  
 
During calcium-dependent NO production, increased intracellular calcium 
stimulates eNOS activity through the activation of calmodulin and subsequent 
displacement of eNOS from caveolin at the plasma membrane, as well as through several 
post-translational events, which include phosphorylation at S1179 of eNOS (29). 
Although a varied assortment of kinases have been shown to phosphorylate eNOS at 
S1179, including PKA, AMPK, CaMKII, Akt, PKG, and PKCα, CaMKII is the 
prominent kinase that promotes activation under calcium-dependent conditions (28, 30). 
Moreover, CaMKII is more sensitive to calcium stimulated activity than PKCα (31). This 
may account for the disparity in recovery of phosphorylation of eNOS S1179 and AS 
S328 that was observed after A23187 treatment following chelation with BAPTA-AM 
(Figure 15). 
  
Although somewhat contentious, there is a growing body of evidence that 
suggests that the calcium-dependent kinase PKCα is active during calcium-mediated 
eNOS stimulation (25, 32, 33). This is in contrast to the calcium-dependent activation of 
PKCβ that was shown to decrease eNOS activity through phosphorylation of T497 (34-
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36), suggesting that different isoforms of PKC may impart different effects in the NO 
production pathway. The involvement of different isotypes of PKC may also explain the 
distinct phosphorylation pattern of AS at S328 from eNOS at T497 in response to 
treatment (Figure 16 and 18). Thus, the contrasting pattern of phosphorylation between 
AS S328, eNOS S1179 and T497 under different treatments with calcium ionophore, 
calcium chelation, and PKC inhibitors was taken to indicate that unique calcium-
dependent kinases participate in phosphorylating these respective sites.  
 
eNOS is also positively regulated in a calcium-independent fashion through 
activation of the PI3K/ AKT pathway which is stimulated by factors such as vascular 
endothelial growth factor (VEGF) and insulin (37). In fact, the observation that calcium-
independent activation of eNOS was associated with a decrease in phosphorylation at 
S328 further supports the involvement of AS regulation at S328 in the calcium mediated 
arm of eNOS dependent NO production (Figure 13). Indeed, several reports have shown 
that stimulating PKCα blunts the effects of VEGF or insulin (23, 24). This relationship 
between PKCα and calcium-independent signaling may explain the observed increase in 
S328 phosphorylation with agents that stimulate PKCα activity, while insulin or VEGF 
decrease S328 phosphorylation. Although the precise role of PKC activation in NO 
production is unsettled (25, 38), in this report, we show PKCα supports NO production 
through the phosphorylation of AS at S328. Because, previous work had shown that 
overall phosphorylation of AS increased in response to VEGF treatment, this suggests 
that other sites of phosphorylation are involved in regulating AS as the result of calcium-
independent signaling. 
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Considering the critical role AS plays in NO production and the spatial and 
temporal manner that eNOS is regulated by calcium levels, it is not surprising that AS is 
susceptible to a regulatory mechanism governed by changes in calcium. Previously, our 
laboratory demonstrated that AS resides in caveolae with eNOS under conditions that 
stimulate NO production, such as stimulation with bradykinin (39). Since PKCα is 
associated with the plasma membrane when activated (40), a functional relationship 
between PKCα and AS may be supported. Furthermore, it has been previously reported 
that changes in intracellular calcium alter the subcellular localization of eNOS (41). 
Therefore, it is tempting to speculate that the phosphorylation of AS at S328 may change 
AS localization in a manner similar to the altered localization of eNOS in response to 
calcium mediated signaling. Experiments are underway to test this hypothesis. 
  
These results overall represent the first demonstration of a biologically relevant 
phosphorylation site for AS, and are consistent with previous findings demonstrating the 
coordinate regulation of eNOS and AS relative to vascular endothelial NO production. 
Given the central role of endothelial NO production in vascular health, future studies, to 
fully characterize the biologically relevant AS phospho-sites, merits further 
consideration.  
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Figure 13. S328 is an exposed site accessible by kinases and shows change in 
phosphorylation relative to treatment. BAECs were transiently transfected with AS 
expression vector then treated with 10µM bradykinin or 50nM okadaic acid. AS was His-
tag purified then subjected to SDS-PAGE. The band corresponding to AS was excised 
and trypsin digested before tandem mass spectrometry analysis. Results represent one 
experiment with samples analyzed in triplicate with SE represented by error bars.  
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Figure 14. Calcium-independent stimulation of NO production decreased 
phosphorylation at argininosuccinate synthase S328. BAECs were treated with insulin at 
100nM (A) or VEGF at 100 ng/mL (C) for 20 min. Phosphorylation was assayed by 
Western blotting using phospho-specific antibodies and reprobed with eNOS and AS 
specific antibodies. Blots are representative of 3 separate experiments. Densitometric 
values (B and D) represent percent change from non-treated (NT) controls normalized to 
total eNOS or AS respectively. Densitometric changes are significant with SE 
represented by error bars (n=3, p< 0.05). (E) Culture media from BAECs treated with 
insulin or VEGF was assayed for nitrite with the DAN assay with SE represented by error 
bars (* n=3, p<0.05). 
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Figure 15. Overexpressed S328 phospho-null mutation to alanine produced significantly 
less stimulated NO than wild type (WT) or phospho-mimetic (S328D). (A) BAECs were 
transiently transfected with wild type (WT), phospho-null serine to alanine 328 (S328A), 
or phospho-mimetic serine to aspartate (S328D) AS then stimulated with 0.5µM calcium 
ionophore A23187 and 50µM sodium orthovanadate. Results are representative of 4 
different experiments with SE noted by error bars. (* p<0.05 relative to WT; † p<0.05 
relative to S328D). (B) Representative western blot confirming WT, S328A, and S328D 
overexpression. 
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Figure 16. Calcium-dependent stimulation of NO production increased phosphorylation 
at argininosuccinate synthase S328. (A) Western blot analysis of changes in 
phosphorylation relative to 20 minute treatment with calcium ionophore (A23187), 
thapsigargin (Thap), in presence or absence of intracellular calcium chelator BAPTA-
AM. Blots are representative of 5 separate experiments. (B) Densitometric values 
represent percent change from non-treated (NT) controls normalized to total eNOS or AS 
respectively. Densitometric changes are significant with SE represented by error bars. (C) 
Culture media from BAECs treated with calcium ionophore (A23187), thapsigargin 
(Thap) in presence or absence of BAPTA-AM was assayed for nitrite with the DAN 
assay. (n=5, significantly increased from NT * , p<0.05, significantly decreased from 
A23187 alone ‡ p<0.05, significantly decreased from Thap alone † p<0.05). 
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Figure 17. Non-isotype specific inhibition of PKC with 42µM rottlerin or 2.5µM 
bisindolylmaleimide I decreased phosphorylation at AS S328. BAECs were pre-treated 
with 42µM rottlerin (Rott) or 2.5µM bisindolylmaleimide I (Bis) for 30 minutes prior to 
stimulation with calcium ionophore (A23187) for 20 minutes. (A) Representative western 
blot of 3 experiments. (B) Densitometric values represent percent change from non-
treated (NT) controls normalized to total eNOS or AS respectively. Densitometric 
changes are significant with SE represented by error bars (n=3, p< 0.05). (C) Culture 
media from treated BAECs was assayed for nitrite with the DAN assay. A23187 
significantly increased NO production with or without bisindolylmaleimide I 
(significance relative to NT: * n=3, p<0.05; significance relative to A23187: ‡ n=3, 
p<0.05).
105 
 
 
 
Figure 18. Knockdown of PKCα decreased phosphorylation at S328 but not eNOS 
S1179. BAECs were treated with 1nM or 5nM dicer substrate RNA (DsiRNA) directed 
against the 5th exon of PKCα and allowed to express for 24 hours, followed by 
stimulation with calcium ionophore A23187 for 20 minutes and compared to non-treated 
(NT) BAECs. (A) Representative western blot of 3 experiments. (B) Densitometric 
values represent percent change from non-treated (NT) controls normalized to total eNOS 
or AS respectively. Densitometric changes are significant (except for A2317 effect on 
PKCα expression or 1nM DsiRNA treatment on pS1179 eNOS) with SE represented by 
error bars (n=3, p< 0.05). (C) Culture media from treated BAECs was assayed for nitrite 
using the DAN assay (significance relative to NT or DsiRNA alone: * n=3, p<0.05) 
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Figure 19. PKCα, but not Akt phosphorylate AS in vitro. (A) In vitro kinase assays. Gray 
bars represent the incubation of purified AS minus kinase (Blank). Black bars represent 
the incubation of purified AS with the indicated kinase (Kinase). Kinase activity is 
represented as counts per minute (CPM) with error bars representing SE (n = 3*, p < 
0.05). (B) Representative autoradiograph of in vitro kinase reactions separated by SDS-
PAGE as described in (A). 
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Figure 20. Working model demonstrating phosphorylation events in response to calcium-
independent (left) or calcium-dependent (right) signaling. (Left) Calcium-independent 
stimulation of eNOS (such as with insulin or VEGF) leads to signaling events that result 
in dephosphorylation of AS. Insulin stimulation activates Akt which phosphorylates 
eNOS at S1179; activation of eNOS noted by arrow pointing to NO. The observed 
decrease in phosphorylation of AS at S328 is likely mediated by a phosphatase (“p-tase”). 
(Right) Calcium-dependent stimulation of eNOS (such as with calcium ionophore or 
thapsigargin) leads to the activation of PKCα and phosphorylation of AS at S328. The 
increase in calcium also activates a number of kinases that can phosphorylate eNOS at 
S1179 (noted by “kinase”) leading to the activation of eNOS and subsequent production 
of NO. 
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PART III: CALCIUM-DEPENDENT STIMULATION OF NITRIC OXIDE 
PRODUCTION LEADS TO CYTOSOLIC CO-LOCALIZATION OF 
ARGININOSUCCINATE SYNTHASE AND ENDOTHELIAL NITRIC OXIDE 
SYNTHASE IN BOVINE AORTIC ENDOTHELIAL CELLS  
 
 
Summary 
Argininosuccinate synthase (AS) catalyzes the rate limiting step in the arginine 
recycling that is required for nitric oxide (NO) homeostasis in endothelial cells. Co-
regulation of AS and endothelial nitric oxide synthase (eNOS) phosphorylation has been 
demonstrated in reponse to calcium mediated stimulation of eNOS in bovine aortic 
endothelial cells (BAECs), although the function of AS phosphorylation at S328 (pS328) 
was not identified. In this report, by utilizing immunofluorescent confocal microscopy, 
we show that phosphorylation of S328 promotes cytosolic localization of AS. 
Furthermore, with membrane enrichment studies, we show that the phospho-mimetic 
mutant S328D AS and endogenous pS328 AS are found only in the cytosol and not 
associated with plasma membrane proteins. Moreover, cytosolic co-localization of eNOS 
and pS328 AS was demonstrated in response to calcium stimulation of BAECs.  These 
results suggest that regulation at S328 promotes cytosolic localization of AS in order to 
provide cytosolic eNOS with substrate. 
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Introduction 
 Argininosuccinate synthase (AS) is a homotetrameric ATPase that is essential in 
the production of the potent vasodilator endothelial nitric oxide (NO) (1). AS and 
argininosuccinate lyase (AL) are responsible for converting citrulline and aspartate to 
arginine, a process termed arginine recycling (2). Arginine recycling and AS expression 
are critical in maintaining levels of the endothelial nitric oxide synthase (eNOS) substrate 
arginine (1, 3). In addition to NO, eNOS produces the citrulline that serves as substrate 
for AS (4). Therefore, the cycling of citrulline to NO production in endothelial cells is 
known as the citrulline-NO cycle (5). Importantly, AS catalyzes the rate-limiting step of 
the arginine recycling required for the citrulline-NO cycle to maintain endothelial NO 
homeostasis (6).  
 
 With regards to citrulline-NO cycle regulation, several mechanisms specific to  
eNOS regulation have been defined (7). An important mode of eNOS regulation occurs 
by modulating eNOS cellular localization or compartmentalization (8). This spatial 
regulation of eNOS is mediated, in part, through protein-protein interaction with 
caveolin-1 (9). Caveolin-1 forms high molecular weight oligomers of > 350 kDa that give 
rise to flask-shaped signaling platforms called caveolae at the plasma membrane (10). 
Caveolin-1 interaction with eNOS inhibits NO production by interfering with eNOS 
association with calcium dependent calmodulin (CaM), a required event for NO 
production (11). Three predicted consensus caveolin binding motifs have been identified: 
ɸXɸXXXXɸ, ɸXXXXɸXXɸ, ɸXɸXXXXɸXXɸ, where ɸ is any aromatic amino acid 
tryptophan, tyrosine, or phenylalanine, and X is any amino acid (12). The interaction of 
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eNOS with caveolin-1 occurs by way of the eNOS caveolin binding motif ɸXXXXɸXXɸ 
(amino acids 350-358) associating with caveolin-1 at amino acids 82-101 (13). As a 
result, dissociation of eNOS from plasma membrane caveolin-1 increases eNOS activity. 
Interestingly, a putative caveolin binding motif ɸXXXXɸXXɸ (bovine sequence 317- 
325) has also been identified in the AS amino acid sequence (Corbin et al, unpublished), 
as well as a phosphorylation site at S328, 3 amino acids away from the putative caveolin 
binding motif. It is currently unknown whether AS associates with caveolin, or if the 
phosphorylation at S328 regulates the potential association. 
 
 Since eNOS dissociation with caveolin-1 promotes eNOS activity, some 
stimulators of NO production, such as bradykinin and calcium ionophore, mediate eNOS 
stimulation, in part, by promoting eNOS cytosolic localization (14-16). Bradykinin and 
calcium ionophore are factors that rely on calcium-dependent stimulation of eNOS. 
Interestingly, calcium-independent activation of eNOS with agents such as insulin or 
VEGF promotes plasma membrane localization of eNOS (17, 18). Under those 
circumstances, eNOS palmitoylation allows plasma membrane localization without 
caveolin-1 interference of activity (19). Consequently, regulation of eNOS localization 
allows NO production to be targeted to particular sub cellular regions (20). Considering 
that AS is a key component of the citrulline-NO cycle, it is logical that AS regulation 
would occur coordinately with eNOS in response to these factors. Indeed, it has been 
recently reported that AS phosphorylation at S328 is co-regulated with eNOS S1179 
(eNOS activating phosphorylation) in response to calcium-dependent stimulation of 
eNOS in bovine aortic endothelial cells (BAECs) (see Part I and II). Taking these 
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observations together, we hypothesized that the calcium-dependent AS phosphorylation 
at S328 promotes cytosolic localization of AS in a coordinate fashion with eNOS. 
 
Experimental Procedures 
Bovine aortic endothelial cell isolation  
 Isolation was performed as described by Schwartz (21) with modifications. Whole 
bovine aortae were obtained within 15 minutes of slaughter from Central Beef Industries, 
LLC (Center Hill, Fl). Aortae were transferred to ice cold isotonic PBS without calcium 
or magnesium and transported to the laboratory on ice. Growing media (20% FBS, 2 mM 
glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin in Dulbecco’s Modified 
Eagle’s Medium (DMEM) with 1 g/L glucose) was prepared and 100 ml was heated to 
37ºC and 100 ml cooled to 4ºC. Isolation of endothelial cells occurred within 2 hours of 
sacrifice. First, excess connective tissue and fat was removed from the exterior of the 
ascending aorta, followed by excess artery removal with a sterile #22 blade scalpel. The 
vessel was then opened longitudinally to expose aortic lumen followed by 5 washes with 
ice cold PBS with 100 U/ml penicillin and 100 mg/ml streptomycin. The rinsed vessel 
was stored in ice cold PBS while the remaining 5 vessels were processed as described. 
After all aortae were processed, cut aorta were individually laid in Petri dish with lumen 
side up, followed by adding drops of 0.1% collagenase on exposed lumen and allowed to 
incubate 10 minutes at room temperature. Sterile swabs soaked with 4ºC growing media 
were used to isolate endothelial cells from the lumen of the collagenase treated vessel 
with a stroke and twist motion, ensuring not to overlap an area twice. Cells were 
dislodged from swabs in 5 ml growing media (4ºC) in a 15 ml conical, then centrifuged at 
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4ºC for 7 minutes at 1000 RPM. Supernatants were discarded and pellet was resuspended 
in 6 ml 37ºC and plated in 25 cm culture flasks overnight at 37ºC and 5% CO2. This 
process was repeated for remaining 5 aortae. Cells were rinsed with PBS and re-fed 
growing media every 2 days until cells reached confluence, then individual culture flasks 
were subcultured into 3, 225 ml flasks. Once cells reached confluence, each flask was 
trypsinized and resuspended in cryopreservation media (growing media with 10% 
DMSO) followed by aliquoting into 6 cryovials and stored at   -80ºC for future use. 
Endothelial cell authentication was achieved by flow cytometry. 
 
Cell culture 
 Cryovials were retrieved from -80ºC and thawed to 37ºC then cells were 
resuspended in 12 ml culture media (10% FBS, 100 U/ml penicillin and 100 mg/ml 
streptomycin, in DMEM with 1 g/L glucose) in 75 cm flask and allowed to grow to 
confluence. Cells between passage 3 and 8 were then subcultured into 15 cm diameter 
culture dishes (Corning) for membrane analysis or immunoprecipitation, or 8 well culture 
slides (BD Falcon), for immunofluorescent confocal microscopy. All cells were serum 
starved for 16 hours prior to15 minute treatment with either 0.5 µM calcium ionophore 
A23187 (Sigma) or 100 nM insulin (Sigma). 
 
Generation of AS plasmid 
 RNA was isolated from BAECs then subjected to reverse transcription with 
random primers to generate a population of random cDNA. Primers specific to AS were 
used to amplify AS cDNA via polymerase chain reaction (PCR). PCR products were 
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analyzed by agarose gel electrophoresis to ensure AS cDNA amplification, then removal 
of dNTPs, unwanted cDNA, and buffer components was achieved with the Qiagen PCR 
clean up kit. Purified PCR product and V5/ 6X His, carbenicillin resistance encoding 
plasmid (pcDNA3.1/ V5 His B) was then restriction digested with Eco RI and Bam H1 
followed by agarose gel electrophoresis, purification of fragments from agarose (Qiagen 
agarose gel purification kit “QiaQuick”), and DNA quantitation. T4 ligase was added to 
100 ng of purified vector was and 8.5 ng AS insert and allowed to incubate at 37ºC for 1 
hour for ligation of AS cDNA to V5/ 6X His plasmid in an orientation that placed V5 and 
His tags at the C-terminus. Ligation product was used to transform competent E. coli with 
the heat shock technique, and cultures were allowed to grow overnight at 37ºC in 100 
µg/ml carbenicillin containing LB broth for plasmid amplification. Each culture was 
restriction digested and analyzed by agarose gel electrophoresis to ensure plasmid 
amplification took place. Positive cultures were then plated on LB/ carbenicillin plates 
and allowed to grow at 37ºC overnight. CFU selection was based on demonstration of 
antibiotic resistance, and isolated colonies were subcultured into 250 ml LB broth with 
carbenicillin and allowed to incubate overnight at 37ºC. E. coli was then pelleted and 
plasmid isolation was achieved using the maxi-prep plasmid purification kit (Sigma). 
Isolated plasmid was ethanol precipitated for further removal of contaminants, then 
quantitated via spectrophotometry. Plasmid preps were sequenced to confirm the 
presence of AS insert (GeneWiz). 
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Site-directed mutagenesis and transient transfection 
 Mutagenesis at S328 of AS was achieved with the QuikChange mutagenesis kit 
(Stratagene). Forward and reverse primers were designed to contain the desired mutation 
in addition to sequence flanking the site of interest. Therefore, for a phospho-null 
mutation at S328, primers encoding alanine in place of serine were generated, and 
aspartate for S328 for phospho-mimetic. Primers used for S328A mutation were sense: 
ACGGGTTTCTGGCACGCGCCCGAGTGTGAATTT and antisense: 
AAATTCACACTCGGGCGCGTGCCAGAAACCCGT. Primers used for S328D 
mutation were sense: ACGGGTTTCTGGCACGACCCCGAGTGTGAATTT and 
antisense: AAATTCACACTCGGGGTCGTGCCAGAAACCCGT. Purified plasmid, 
primers, dNTPs, reaction buffer, and Pfu polymerase were mixed then placed in a 
thermocycler for PCR. Pfu polymerase is used in this reaction because of its high fidelity 
and increased thermostability. Mutated constructs were sequenced for confirmation of 
mutagenesis (GeneWiz). 
 
 For transfection, subconfluent BAECs grown in 15 cm culture dishes were 
transiently transfected with either wild type (WT), S328A, or S328D AS constructs. 
Lipofectamine 2000 (462 µl) was mixed with reduced serum media Opti-Mem (14.4 ml) 
(Invitrogen) and allowed to incubate at RT for 5 minutes. Plasmid DNA was diluted to 
the same concentration then 17 µg of each plasmid was added to 4.8 ml Opti-Mem. 
Lipofectamine/ Opti-Mem mixture (4.8 ml) was added to each aliquot of diluted DNA 
and allowed to incubate 20 minutes. Media of BAECs in 15 cm culture plates was 
exchanged to 25 ml transfection media (1 g/L glucose DMEM, 10% FBS), then 4.6 ml of 
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each DNA mixture was added to respective dishes and allowed to incubate at 37ºC in 5% 
CO2 for 4 hours. Cells were washed with PBS then 25 ml fresh 37ºC transfection media 
was added to each plate. Cells were allowed to express transfected plasmid overnight 
before further analysis. For BAEC transfection on 8-well culture slides, the same 
procedure was performed with reagent volumes reduced to area equivalents.  
 
Immunofluorescence and confocal microscopy 
 Cultured cells between passage 3 and 6 were grown to subconfluence on 8-well 
treated culture slides, then serum starved overnight for experiments where cells were 
treated with calcium ionophore or insulin. For transfection experiments, cells were 
transfected as described above then subjected to immunofluorescence the following day.  
On day of immunofluorescence, slides were washed with isotonic PBS 2 times to remove 
media then fixed in 3.7% paraformaldahyde at 37ºC and 5% CO2 for 15 minutes. Cells 
were washed 2 times for 5 minutes each with PBS, then permeabilized with 0.1% Triton 
X at RT for 10 minutes. Slides were washed as before, then blocked with 10% normal 
goat serum (Invitrogen) for 30 minutes. Primary antibodies directed against pS328 AS 
(rabbit), V5 (mouse, Invitrogen), or eNOS (mouse, BD Transduction Laboratories) were 
added to indicated wells (1/100 dilution in 10% normal goat serum) and allowed to 
incubate 1 hour. Buffer was removed then cells were washed 3 times for 5 minutes each 
with PBS. Secondary antibodies (goat anti-rabbit Alexa 488 and goat anti-mouse Alexa 
594) at 1/1000 in 10% normal goat serum were added and allowed to incubate 1 hour. 
Cells were washed 3 times at 5 minutes each with PBS then wells were removed, and 
DAPI nuclei stain with anti-fade reagent was added. Slides were topped with a cover slip 
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then sealed with Hard as Nails clear fingernail polish (Sally Hansen) and frozen at -20ºC 
until analysis at confocal microscopy core the following day. Cells were viewed at 60X 
oil immersion with an Olympus FV1000 MPE multiphoton laser scanning microscope 
(USF Microscopy Core). Images were analyzed qualitatively for membrane localization 
or co-localization of pS328 AS and eNOS represented by yellow. Observed interactions 
or localizations were confirmed with membrane enrichment techniques or 
immunoprecipitation. 
 
Conconavalin A membrane protein enrichment 
 To isolate membrane components for analysis of associated proteins, the 
concanavalin A (Con A) technique from Lee et al was used(22), where conjugated 
magnetic beads were utilized to sequester plasma membranes from lysed BAECs. For 
conjugation, streptavidin coated beads were washed then resuspended in TBS followed 
by the addition of biotinylated Con A to resuspended magnetic beads and allowed to 
incubate with agitation for 1 hour.. Beads were then washed to remove unbound Con A 
then resuspended in TBS for future use. BAECs were grown to confluence as described 
above then collected in ice cold TBS by scraping. Cells were washed then resuspended in 
TBS with protease and phosphatase inhibitors (Pierce). Lysis of cells was achieved by 
sonication at 80 W in 4, 10 second bursts with 20 second break between bursts with tubes 
on ice. Lysate was then added to prepared beads and allowed to incubate for 1 hour with 
rotisserie agitation. After incubation, beads were pelleted with a magnet then unbound 
supernatant was collected and considered the cytosolic fraction. Beads were washed with 
ice cold TBS 4 times with beads transferred to new tube at the third wash. To elute bound 
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proteins, 75 µl elution buffer (0.25 M methyl α-D glucoside, 0.5% CHAPS, and protease/ 
phosphatase inhibitor cocktail in TBS) was added to beads then pelleted with magnet, 
then elution was repeated and elutions were combined. Analysis of eluted proteins was 
performed by western blot (see Part I, page 31 for western protocol). 
 
Membrane protein solubilization with organic solvents 
 In order to solubilize membrane components and their associated proteins, 
membrane fractions were subjected to further solubilization with the Mem-PER kit 
(Pierce) which utilizes organic solvents to solubilize hydrophobic proteins found in the 
membrane. First, BAECs transfected with WT, S328A, or S328D AS, or no transfection 
were lysed with RIPA lysis buffer. Lysates were centrifuged at 4ºC for 15 minutes at 
15,000 RPM then supernatants were removed. The insoluble pellet was washed with PBS 
then reagents A, B, and C were added to the pellet as described by the manufacturer 
followed by incubation of tubes on ice for 30 minutes with vortexing every 5 minutes. 
Tubes were centrifuged at 10,000 X g for 3 minutes and supernatants were transferred to 
new tubes. The remaining procedure for separating hydrophobic from hydrophilic 
proteins was not performed because the objective was only to solubilize the insoluble 
fraction. The solubilized proteins were resolved via SDS-PAGE and analyzed by western 
blotting. 
 
Immunoprecipitation 
Selected antibodies (rabbit polyclonal anti-eNOS, BD Transduction Laboratories; 
or goat polyclonal anti-AS, AbCam) were conjugated to magnetic beads using M270 
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Epoxy (Invitrogen) and stored at 4ºC less than 2 days prior to immunoprecipitation. Cells 
were grown in 15 cm diameter dishes to subconfluence as described above prior to either 
100 nM insulin treatment or transfection. First, media was removed and cells were 
washed 2 times with ice cold PBS. Cells were lysed by 30 minute incubation with 
agitation in low detergent RIPA buffer (150 mM sodium chloride, 1% NP-40, 50 mM 
Tris at pH 8.0, 0.1% Brij 35, and protease and phosphatase inhibitor cocktail) then 
scraped into 2 ml tubes and centrifuged at 15,000 RPM at 4ºC for 15 minutes to remove 
insoluble material. BCA protein assay (Pierce) was performed to assess protein 
concentration of supernatants, then 2 mg protein from insulin treated lysates or non-
treated lysates was added to anti-eNOS conjugated magnetic beads, or 2 mg protein from 
lysates of transfected BAECs was added to anti-AS conjugated magnetic beads and 
allowed to incubate on rotisserie mixer overnight at 4ºC. The following day, beads were 
pelleted and washed with low detergent RIPA buffer 4 times. Bound proteins were eluted 
with an acidic elution buffer (Invitrogen) then analyzed by western blot (see Part I, page 
31 for western blot procedure). 
 
Endogenous AS silencing and mutant AS overexpression 
 To knockdown endogenous AS, siRNA directed against AS at nucleotides 73-94 
with the sequence 5’-AAGGAGCAAGGCTATGACGTCATTGCC- 3’ was used as 
described by (1). S328A, S328D and WT AS constructs were mutated with silent 
mutations (SM) at nucleotides 81 and 84 region with the forward primer 5' 
CTCGTGTGGCTGAAGGAGCAGGGATATGACGTCATTGCCTACC 3’ and reverse 
primer 5’ GGTAGGCAATGACGTCATATCCCTGCTCCTTCAGCCACACGAG 3’ 
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using the QuikChange kit (Stratagene) as described above. Co-transfection of siRNA and 
S328A-SM, S328D-SM, or WT-SM AS in BAECs grown to subconfluence in 12-well 
plates was performed as described above, then cells were allowed to express siRNA and 
AS constructs for 48 hours. Media was exchanged to arginine and serum free media (1 
g/L glucose DMEM without phenol red, arginine, leucine, lysine, or sodium pyruvate 
(Sigma), replenished with citrulline and all removed components except arginine) 
supplemented with 0.1% BSA and allowed to arginine starve for 2 hours. Cells were then 
given fresh arginine free media and allowed to incubate overnight at 37ºC and 5% CO2. 
After 16 hours, media aliquots were taken for NO determination with the DAN assay (see 
Part I page 35 for DAN assay procedure). 
 
Results 
Redistribution of AS occurs as a result of S328 mutation 
 In a previous study, we established that increased intracellular calcium leads to 
S328 phosphorylation (see Part II). Since eNOS translocates to the cytosol upon calcium 
stimulation, we sought to determine whether regulation of AS at S328 leads to altered 
subcellular localization as well. Therefore, we used site-directed mutagenesis to mutate 
S328 to phospho-mimetic aspartate (S328D) or alanine for a phospho-null mutation 
(S328A) from a V5 tagged plasmid containing non-mutated AS (WT) for overexpression 
in BAECs. We then performed immunofluorescent confocal microscopy using anti-V5 
antibody to observe changes in localization of AS relative to the mutation. As shown in 
Figure 21, non-mutated WT AS was noted to have cytosolic and membrane localization, 
indicated by the arrows. However, there was considerable membrane localization 
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observed by the phospho-null S328A mutation (Figure 21, middle). Conversely, the 
S328D AS mutation led to a largely cytosolic distribution when overexpressed (Figure 
21, right). These results suggest that the phospho-null moiety of AS may localize to the 
plasma membrane. 
 
Phospho-null S328A AS is enriched in membrane fraction 
 In order to corroborate the observation from microscopy that S328A is associated 
with the plasma membrane, we sought to determine whether different mutations at S328 
affect its association with membrane components. Since membrane components are 
largely insoluble, membrane protein solibilization of BAECs overexpressing WT, S328A, 
or S328D AS was performed using the Mem-PER membrane protein solubilization kit 
(Pierce) in order to solubilize membrane and membrane associated proteins such as AS. 
As expected, non-transfected cells showed that some AS was found associated with 
solubilized membrane proteins, which corroborates previous findings (Figure 22). 
However, WT and S328A transfected cells showed robust detection of AS in solubilized 
plasma membrane components (Figure 22). In contrast, the phospho-mimetic S328D 
overexpressing cells showed very little AS associated with solubilized membrane 
proteins, similar to that of non-transfected cells (Figure 22). These data are consistent 
with the confocal images showing the phospho-null S328A associates with the plasma 
membrane, and phospho-mimetic S328D does not.  
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Total AS, but not endogenous pS328 AS, is found in the membrane enriched fraction 
 After observing changes in AS localization relative to the S328 mutation, the 
localization of endogenously phosphorylated S328 AS was assessed. In these 
experiments, we used the concanavalin A (Con A) plasma membrane enrichment 
technique rather than the plasma membrane solubilization in order to demonstrate 
consistency in results across different methodologies. Con A is a lectin that binds 
glycosylated moieties on the plasma membrane. In this assay, biotinylated Con A is 
immobilized to streptavidin coated magnetic beads followed by incubation with cell 
lysate to bind plasma membranes. Beads are washed for removal of cytosolic proteins 
and membrane components are displaced with use of a high sugar concentrated solution 
to elute proteins of interest. Since pS1179 eNOS is known to associate with the plasma 
membrane, identification of pS1179 eNOS was used as a positive control. Western of 
caveolin-1 enrichment was used to show that membrane protein enrichment was 
achieved. When non-treated BAECs were subjected to Con A fractionation, total AS was 
found to associate with the plasma membrane, however, endogenously phosphorylated 
pS328 AS was found only in the cytosol (Figure 23). These results support the previous 
findings that identified overexpressed S328D AS is cytosolic in that endogenous 
phosphorylation of AS at S328 was found only in the cytosolic fraction after membrane 
protein enrichment. 
 
Phospho-null and wild type AS, but not phospho-mimetic AS, associate with caveolin 
 Since S328 is 3 amino acids away from a putative caveolin binding motif of AS, 
the association of S328A, S328D, and WT overexpressed AS with caveolin was 
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determined. BAECs were transiently transfected with either construct as described above. 
Lysates were then immunoprecipitated with anti- AS antibody, and non-transfected cells 
were immunoprecipitated with anti-V5 antibody as negative control. Eluates from each 
immunoprecipitation were then assayed for caveolin via western blot. As shown in Figure 
24, immunoprecipitated WT AS and phospho-null S328A AS co-precipitated caveolin-1. 
However, immunoprecipitated S328D AS, or immunoprecipitated anti-V5 in negative 
control lysates, did not co-precipitate caveolin. These results suggest that non-
phosphorylated S328 AS, but not phosphorylated S328 AS associates with caveolin, and 
presumably the plasma membrane.  
 
pS328 AS and eNOS co-localize in cytosol upon calcium stimulation 
 Since it has been established that eNOS translocates to the cytosol in response to 
calcium mediated stimulation in endothelial cells, and our results indicate that AS 
translocates to the cytosol as well, we sought to determine whether AS and eNOS co-
localize in the cytosol as the result of calcium-mediated stimulation. BAECs were grown 
on culture slides then cells were stimulated with calcium ionophore, insulin, or nothing, 
then probed for pS328 AS (green) and eNOS (red) (Figure 25). Non-treated BAECs 
showed some pS328 AS and eNOS co-localization (yellow) in the perinuclear region, 
however, upon calcium stimulation, robust co-localization of pS328 AS and eNOS was 
observed in the perinuclear region. Conversely, cells stimulated with insulin showed 
eNOS strongly associated with the plasma membrane, yet little pS328 AS was localized 
with eNOS or detected overall. These results suggest that calcium stimulation promotes 
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eNOS and pS328 AS co-localization in the perinuclear region, and pS328 AS and eNOS 
do not associate under insulin stimulation. 
 
Total AS and eNOS associate upon insulin stimulation 
 From the confocal microscopy, it appeared that eNOS and pS328 associate at 
basal conditions, but do not associate with insulin stimulation. Therefore, to demonstrate 
a physical interaction between AS and eNOS, immunoprecipitation of eNOS was 
performed with non-treated or insulin treated BAEC lysates to observe pS328 AS or non-
phosphorylated AS (48 kDa) co-precipitation relative to insulin treatment. When eNOS 
was immunoprecipitated, pS328 was found to co-precipitate in non-treated BAEC lysates 
(Figure 26). However, when cells were treated with insulin, robust co-precipitation of 
48kDa AS was found in the eNOS immunoprecipitation eluate. These results support the 
observations from confocal microscopy that pS328 AS associates with eNOS under non-
stimulated conditions, and that non-phosphorylated AS associates with eNOS when 
stimulated with insulin.  
 
Phospho-mimetic and phospho-null AS have same enzymatic activity as WT 
In order to establish whether regulation at S328 affects enzymatic activity of AS, 
S328A, S328D or WT AS constructs were overexpressed in BAECs with endogenous AS 
knocked down, then NO production was assessed. S328A, S328D, and WT constructs 
were designed to have silent mutations in the region that the siRNA bound, allowing only 
endogenous AS to be susceptible to the siRNA. As shown in Figure 27, WT AS 
overexpression effectively recovered NO production relative to AS knockdown alone. 
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Additionally, overexpression of S328A and S328D AS recovered NO production in a 
manner consistent with WT AS overexpression. These data suggest that regulation at 
S328 does not affect enzymatic activity of AS. 
 
Discussion 
 Since endothelial stimulation with factors that rely on increased intracellular 
calcium lead to eNOS cytosolic translocation (14-16), we investigated whether the 
calcium-dependent phosphorylation of AS at S328, positioned near a putative caveolin 
binding motif, promoted a cytosolic translocation of AS as well. Using site-directed 
mutagenesis to generate the phospho-null S328A and phospho-mimetic S328D AS 
constructs, we identified altered localization patterns and protein-protein interactions of 
AS relative to S328 mutation compared to wild type (WT) AS. We then confirmed 
changes in localization predicted by S328 mutation experiments through analysis of 
endogenous pS328 AS localization. 
 
We have previously observed decreased phosphorylation at S328 of AS in 
response to calcium-independent stimulation with insulin or VEGF (Part II), as well as 
established a proximal relationship between enzymes in the citrulline-NO cycle (23). 
Since it is well established that insulin mediates plasma membrane localization of eNOS 
(17), we hypothesized that the phospho-null S328A AS may co-localize with eNOS in 
response to calcium- independent stimulation of eNOS. Moreover, we suspected that a 
possible role of phospho-null S328 AS may be to localize to the plasma membrane to 
provide arginine recycling for plasma membrane localized eNOS. Indeed, the phospho-
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null S328A AS showed increased membrane localization via immunofluorescent 
confocal microscopy relative to WT or phospho-mimetic S328D AS. Furthermore, we 
showed that S328A AS protein was also enriched when plasma membrane proteins were 
solubilized and assayed by western blot, indicating that the phospho-null form of AS is 
associated with plasma membrane components. Consistent with this data, 
immunoprecipitation of S328A, S328D, or WT showed caveolin, a plasma membrane 
protein, in eluates of S328A and WT transfected cells. Furthermore, immunoprecipitation 
of eNOS after insulin stimulation showed co-precipitation of the 48 kDa non-
phosphorylated AS moiety that did not co-precipitate under non-stimulated conditions. 
Taken together, these data suggest that the phospho-null S328 moiety of AS associates 
with eNOS via protein-protein interaction with caveolin during calcium-independent 
stimulation of endothelial cells. 
 
Since phosphorylation at S328 is calcium-dependent, the identification of a 
calcium sensitive regulatory mechanism proximal to a caveolin binding motif led us to 
hypothesize that S328 phosphorylation may promote a cytosolic translocation of AS 
similar to eNOS translocation in response to calcium. From immunofluorescent confocal 
microscopy, we identified diffuse expression of phospho-mimetic S328D AS throughout 
the cytosol, suggesting that S328D does not have an affinity for the plasma membrane. 
Consistant with this observation, overexpressed S328D AS was not associated with 
solubilized plasma membrane proteins. These results, in conjunction with the 
juxtaposition of S328 to a putative caveolin binding motif of AS, led us to address the 
question regarding the ability of S328D AS to interact with caveolin. 
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Immunoprecipitation of overexpressed phospho-mimetic S328D AS showed that caveolin 
did not co-precipitate with S328D AS, suggesting that S328 phosphorylation negatively 
affects AS-caveolin interaction. These results support the idea that S328 phosphorylation 
may impair AS association with the plasma membrane and thus lead to cytosolic 
localization. In addition, we corroborated overexpression experiments by evaluating the 
cellular distribution of endogenous pS328 AS by membrane enrichment and 
immunofluorescent confocal microscopy. Similar to overexpression experiments, 
endogenous pS328 AS was identified only in the cytosolic fraction after Con A plasma 
membrane enrichment of BAECs. Endogenous pS328 AS also showed cytosolic 
distribution AS in confocal microscopy, again agreeing with observed S328D cellular 
distribution. Collectively, these data demonstrate by observation of endogenous pS328 
AS and exogenous S328D in confocal microscopy and membrane fractionation, that 
phosphorylation at S328 promotes cytosolic distribution of AS. 
 
In order to visually evaluate the effect of calcium or insulin stimulation on 
endogenous pS328 AS and eNOS localization, immunofluorescent confocal microscopy 
with cells treated with calcium ionophore or insulin was conducted. Importantly, we 
showed perinuclear co-localization of pS328 AS and eNOS increased relative to calcium 
stimulation, and relatively no pS328-eNOS co-localization with insulin treatment. 
Furthermore, we showed that eNOS and pS328 physically associate in that 
immunoprecipitation of eNOS co-precipitated pS328 AS, thus corroborating confocal 
microscopy data. These data indicate that a function of pS328 AS may be to co-localize 
with cytosolic eNOS to provide site specific arginine recycling. To this end, we were 
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interested in determining whether regulation at S328 affects the activity of the AS 
enzyme. Transfection with WT, S328A or S328D AS, in BAECs with endogenous AS 
knocked down, showed no change in NO production relative to the mutation, indicating 
that modification at S328 of AS does not affect enzymatic activity. The demonstration 
that S328 modification does not affect AS activity suggests that the sole function of S328 
phosphorylation is to modulate AS localization. Above all, the present study suggests that 
the proximal relationship of AS and eNOS is a key factor in maintaining the citrulline-
NO cycle in endothelial cells. 
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Figure 21. Phospho-mimetic S328D mutation promotes cytosolic distribution of AS. 
BAECs were transiently transfected with either wild type (WT, left), phospho-null 
(S328A, middle) or phospho-mimetic (S328D, right) AS. Immunofluorescence was 
performed with mouse anti-V5 primary antibody and goat anti-mouse secondary antibody 
conjugated to alexa-488. Images were obtained with an Olympus FV1000 MPE 
multiphoton laser scanning microscope at 60X with oil immersion. Arrows indicate areas 
of acute V5 detection. Images are representative of 3 separate experiments. 
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Figure 22. Phospho-mimetic S328D mutation diminishes AS detection in solubilized 
BAEC membrane proteins. BAECs were either not transfected (first lane), or transiently 
transfected with wild type AS (WT, second lane), phospho-null S328A (third lane, or 
phospho-mimetic S328D (fourth lane) mutated AS. Cells were lysed with RIPA then 
insoluble material was retrieved and washed. Insoluble membrane components were 
solubilized and analyzed by western blot. Results are representative of 2 experiments. 
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Figure 23. Endogenous phospho-null S328 AS, but not phospho-S328 AS, is found in the 
membrane enriched fraction of BAEC lysates. BAECs were grown to confluence then 
lysed by sonication. Magnetic beads conjugated to the lectin Con A were used to 
immobilize glycosylated membrane components followed by wash and elution of 
membrane and membrane associated components. Analysis of elutions was performed by 
western blot. eNOS pS1179 was used as positive control for enrichment of membrane 
associated proteins, and caveolin-1 detection was used to confirm of membrane 
enrichment. Results are representative of 2 experiments. 
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Figure 24. Caveolin-1 co-precipitated with WT and phospho-null S328A overexpressed 
AS, but not S328D overexpressed AS. BAECs were transiently transfected with either 
wild type (WT), phospho-null (S328A) or phospho-mimetic (S328D) AS, lysed with low-
detergent lysis buffer, then immunoprecipitated with anti-AS antibody. 
Immunoprecipitation with anti-V5 antibody (used as non-specific IgG) was performed 
with non-transfected cell lysates as negative control. Eluates were analyzed for presence 
of caveolin-1 by western blot. Results are representative of 1 experiment. 
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Figure 25. Calcium stimulation of BAECs promotes cytosolic co-localization of 
endogenous phospho-S328 AS and eNOS. BAECs were grown on culture slides then 
treated with either nothing (left), calcium ionophore (middle), or insulin (right). Cells 
were analyzed by immunofluorescence with primary antibodies rabbit anti-phospho-S328 
and mouse anti-eNOS, and secondary antibodies goat anti-rabbit alexa-488 and goat anti-
mouse alexa-594. Green represents phospho-S328 detection, red eNOS detection, and 
yellow denotes co-localization. Arrows indicate co-localization in non-treated cells and 
calcium ionophore cells. In insulin treated cells, bottom arrow points to eNOS plasma 
membrane localization, upper arrow points to absence of co-localization. Results are 
representative of 3 experiments. 
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Figure 26. Insulin promotes phospho-null S328 AS association with eNOS. BAECs were 
grown to confluence, serum starved overnight, then treated with or without insulin. 
Lysates were immunoprecipitated with anti-eNOS antibody then eluates were analyzed 
for pS328 or AS co-precipitation by western blot. Results are representative of 2 
experiments. 
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Figure 27. AS activity is not affected by phospho-null or phospho-mimetic mutation of 
S328. Endogenous AS was knocked down in BAECs, then were transiently transfected 
with either WT, phospho-null S328A, or phospho-mimetic S328D AS constructs. 
Extracellular NO production was assessed with the DAN assay. Values are plotted as 
pMol nitrite per microgram protein. Data represents the results from 4 experiments. 
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DISCUSSION 
 
 
Endothelial function is defined by the ability to efficiently produce nitric oxide 
(NO). NO homeostasis is critical in preventing thrombus formation, overexpression of 
endothelial adhesion molecules, and promoting vasodilation. The production of 
endothelial NO occurs through the citrulline-NO cycle that involves the catalysis by three 
enzymes: argininosuccinate synthase (AS), argininosuccinate lyase (AL), and endothelial 
nitric oxide synthase (eNOS). AS and AL recycle eNOS derived citrulline back to 
arginine to serve as eNOS substrate for the production of NO. Importantly, AS catalyzes 
the rate-limiting step in the arginine recycling associated with NO production. 
Furthermore, inhibiting AS expression and preventing endothelial cells from recycling 
arginine from citrulline leads to inhibition of NO production and endothelial apoptosis. 
Therefore, arginine recycling is a critical aspect of the citrulline-NO cycle, and the 
regulation of eNOS and AS is essential in maintaining endothelial function. The work 
described here is the result of investigating the role that acute regulation of AS by 
phosphorylation at serine 328 (S328) plays in the citrulline-NO cycle.  
 
Several mechanisms describing the regulation of eNOS activity have been 
elucidated, including phosphorylation, lipid modification, and protein-protein 
interactions. However, much less has been established relating to the regulation of AS in 
endothelial cells. What has been demonstrated is that AS is co-regulated with eNOS at 
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the level of transcription in response to several physiological factors including shear 
stress (1), PPARγ agonist troglitazone, insulin (2), and TNFα (3). Furthermore, it has 
been demonstrated that AS and eNOS have a proximal relationship at caveolae in 
endothelial cells (4). Since NO is a readily diffusible free radical that cannot be 
intracellularly stored, the spatial and temporal regulation of NO production is imperative 
in order to mediate endothelial function. Given that AS and eNOS are co-regulated 
transcriptionally and have been demonstrated to have a proximal relationship, it is logical 
to hypothesize that AS is regulated spatially and temporally with eNOS in order to meet 
the cellular demands for NO. Since phosphorylation is a type of post-translational 
modification associated with mediating acute changes in subcellular localization and 
activity, we pursued the hypothesis that AS is phosphorylated, and AS phosphorylation 
plays a role in NO production.  
 
In order to evaluate the possibility that AS and eNOS are co-regulated by 
phosphorylation, we first demonstrated that AS exists as a phospho-protein in endothelial 
cells (5). Subsequently, we analyzed the AS protein by mass spectrometry to identify 
potential phosphorylation sites. In order to identify phosphorylation sites associated with 
a response to physiological cues, AS was purified from BAECs treated with factors 
known to increase phosphorylation of eNOS, such as bradykinin or okadaic acid 
(phosphatase inhibitor). From this analysis, we identified the candidate phosphorylation 
site serine 328 (S328). We then analyzed the impact of mutating the site to phospho-null 
(S328A) or phospho-mimetic (S328D) on calcium ionophore stimulated NO production 
when constructs were overexpressed in BAECs. Results indicated that WT and phospho-
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mimetic S328D constructs supported calcium stimulated NO production, while the 
phospho-null S328A construct yielded significantly less NO production. These results 
suggested that phosphorylation at S328 may play a role in supporting NO production. As 
a result, we subsequently generated a phospho-S328 specific antibody for further 
characterization of phosphorylation at S328. 
 
In order to understand the conditions associated with AS phosphorylation at S328, 
we treated cultured endothelial cells with several physiological factors known to 
modulate NO production. Several types of stimulators of NO production (acetylcholine, 
calcium ionophore, bradykinin, insulin, VEGF, lysophosphatidic acid, sodium vanadate, 
Nor-NOHA, and estradiol) were used, in addition to NO production inhibitors (free fatty 
acid, TNFα, homocysteine, and ADMA). The results from these experiments showed that 
AS S328 and eNOS S1179 (activates eNOS) were coordinately regulated in response to 9 
out of 13 treatments. In addition, the factors that stimulate eNOS activity in a calcium 
dependent manner promoted S328 phosphorylation, while Akt mediated eNOS 
stimulation (calcium-independent eNOS activation) led to a decrease in S328 
phosphorylation. Similarly, factors that lead to a decrease in intracellular calcium led to 
diminished phosphorylation of AS at S328. From these experiments, we concluded that 
S328 phosphorylation was co-regulated with eNOS in response to factors that alter 
intracellular calcium.  
 
After establishing that phosphorylation at S328 was co-regulated with eNOS 
S1179 under certain conditions, we then hypothesized that the AS phosphorylation at 
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S328 was calcium-dependent, and that a calcium dependent kinase may phosphorylated 
AS. Results showed that calcium and thapsigargin stimulation of cultured endothelial 
cells led to increased phosphorylation at S328, while chelating intracellular calcium with 
BAPTA-AM completely abolished S328 phosphorylation of AS. Furthermore, kinase 
inhibition and gene knockdown studies suggested that S328 is phosphorylated by the 
calcium-dependent kinase PKCα. Since PKCα is not activated by insulin or VEGF 
signaling, this agrees with previous data indicating that S328 phosphorylation is 
associated with calcium dependent stimulation of eNOS. We concluded from this work 
that AS phosphorylation at S328 is indeed calcium-dependent and is mediated by PKCα. 
 
After establishing the circumstances that promote S328 phosphorylation of AS, 
we were interested in determining the function of pS328 AS. Since eNOS translocates to 
the cytosol upon calcium stimulation, we hypothesized that a potential function of 
phosphorylation at S328 occuring in a calcium-dependent manner may be to translocate 
AS from plasma membrane to the cytosol with eNOS. Further support for this hypothesis 
was based on the fact that activated PKCα is associated with the plasma membrane, 
therefore S328 phosphorylation may occur at the plasma membrane to initiate a 
translocation event. In support of this hypothesis, a putative caveolin binding motif, 3 
amino acids away from S328, was identified in the AS protein sequence. Therefore, we 
performed site directed mutagenesis at S328 to observe changes in localization by 
immunofluorescence and membrane fractionation. In addition, we immunoprecipitated 
mutated AS and analyzed co-precipitates for the membrane associated protein caveolin-1, 
which was predicted to associate with AS near S328. Results showed that the phospho-
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mimetic mutation at S328 (S328D) promoted cytosolic localization and absence of 
caveolin-1 interaction, while the phospho-null mutation (S328A) showed membrane 
localization and caveolin-1 interaction. Furthermore, we showed co-precipitation of non-
phosphorylated AS with eNOS when BAECs were treated with insulin. However, pS328 
AS, but not non-phosphorylated AS, associated with eNOS when cells were untreated. 
These data suggest that 1) S328 phosphorylation negatively regulates AS interaction with 
caveolin, 2) insulin promotes AS association with plasma membrane localized eNOS, 3) 
calcium promotes AS association with cytosolic localized eNOS. Furthermore, since the 
activity of AS was not affected by S328 mutation, these results indicate that the role of 
phosphorylation at S328 is primarily to modulate the localization of AS to maintain 
proximity to cytosolic eNOS in response to calcium. 
 
Regardless of the manner in which eNOS is stimulated relative to calcium, the 
bulk intraendothelial arginine concentration at any given point far exceeds the eNOS 
Michealis-Menton constant (Km), yet eNOS is rarely saturated with substrate. This 
phenomenon is referred to as the "arginine paradox", and several potential mechanisms 
have been offered to explain the basis for this contrariety. For example, experiments 
performed by McDonald and others suggested that the neutral amino acid transporter, 
CAT 1, channels exogenous arginine to eNOS since inhibition of eNOS association with 
CAT 1 attenuated arginine uptake by endothelial cells (6). However, Venema and others 
showed that inhibition of arginine uptake by saturating the transporter with lysine did not 
decrease the degree of NO output (7). These findings suggested that the observed 
increase in NO is not dependent on arginine uptake through CAT1, but rather the protein-
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protein interaction of eNOS with the transporter. These experiments raise doubt relating 
to the CAT 1 channeling of arginine to eNOS, but do not address the likely source of 
arginine for eNOS. The data presented in this report suggested that the maintenance of 
sequestered arginine pools by argininosuccinate synthase in the proximity of eNOS is 
required to maintain NO homeostasis. Since NO signaling in endothelial cells and other 
tissue types (neurons, macrophage, etc) is critical for survival, a localized 
microenvironment of accessible arginine by eNOS is essential, since it is well established 
that the arginine consuming enzyme arginase competes with eNOS for substrate. That 
being the case, the presence of proximal relationship between eNOS and arginine 
recycling from citrulline ensures that a constant supply of arginine is available to eNOS 
in order to maintain cell viability and function. As a result, a basal level of intracellular 
and/or extracellular NO production can be maintained despite conditions of diminished 
substrate availability by arginase. For these reasons, a logical explanation to the arginine 
paradox is that the co-regulation of AS and eNOS localization supports the maintenance 
of the eNOS arginine microenvironment in the endothelial response to factors that 
promote changes in eNOS subcellular distribution or substrate competition.  
 
Surprisingly, the implications of cytosolic eNOS localization and intracellular NO 
production have not been fully defined. What has been defined is that intra-endothelial 
NO production is required to S-nitrosylate cysteine 163 of caspase 3, thereby inhibiting 
the caspase cascade that leads to endothelial cell apoptosis. In addition, ER localized 
eNOS has been suggested to play a role in S-nitrosylation of other proteins. However, S-
nitrosylation, in most circumstances, is considered a non-specific cellular response to 
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oxidative stress rather than specific alteration of particular pathways, as is the case with 
phosphorylation. For example, increased oxidative stress and reactive nitrogen species 
leads to S-nitrosylation of cellular proteins, which allows them to adapt to the altered 
redox state (i.e. prevents protein oxidation or degradation) (8). It is not likely that the sole 
purpose of cytosolic NO production is to mediate redox adaptation, since bradykinin, a 
physiological stimulator of NO production and vasodilation, does not promote oxidative 
stress (9), yet has been shown to stimulate eNOS cytosolic translocation (10, 11). 
Furthermore, the measurement of intracellular NO and extracellular NO is rarely 
performed in the same experiment, however, when the two methods are used, the two sets 
of data seldom agree. For example, it is often reported that intracellular localized eNOS 
(i.e. myristoylation mutant G2A eNOS) is less active than wild type eNOS, however, the 
method to detect NO production in these experiments utilized extracellular culture media 
and did not account for intracellular NO production (12). If the cytosolic eNOS that 
generates intracellular NO is generated and consumed by the endothelial cell, it would 
likely not be detected in extracellular culture media. Indeed, Church et al showed that the 
eNOS myristoylation mutant generated significantly less NO than WT eNOS when NO 
production was assayed from culture media, however, upon cellular disruption, the eNOS 
myristoylation mutant was found to actually generate more NO than WT (13). This 
suggests that the myristoylation mutant is active, but its product is not detected as 
efficiently in culture media. This further supports the idea that intracellular eNOS 
generates NO that does not reach outside the cell. These observations may lead one to 
surmise that intracellular NO production may serve a role specific to endothelial biology 
in addition to the other well characterized NO signaling mechanisms. 
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Relative to these details, the observation that impaired intracellular NO 
production results in apoptosis implies that maintaining intracellular NO levels is critical 
to endothelial function. Our results here suggested that AS co-localizes with eNOS at the 
plasma membrane in response to insulin, whereas calcium stimulation led to AS co-
localization with eNOS in the cytosol, thereby setting the stage for multiple sites of 
citrulline-NO cycle activity. Given these points, it is tempting to hypothesize that 
cytosolic co-localization of AS and eNOS promotes intracellular NO production, and 
therefore plays a significant role in intra-endothelial signaling and function, beyond what 
is known relative to nitrosylation or prevention of apoptosis. Further investigation 
relating to additional functions of the citrulline-NO cycle regarding intracellular NO 
production in endothelial function may give insight relative to pathologies associated 
with the vascular endothelium.  
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APPENDIX:  
INSULIN TRANSCRIPTIONALLY REGULATES ARGININOSUCCINATE 
SYNTHASE TO MAINTAIN VASCULAR ENDOTHELIAL FUNCTION
2
 
 
Summary 
Diminished vascular endothelial cell nitric oxide (NO) production is a major 
factor in the complex pathogenesis of diabetes mellitus. In this report, we demonstrate 
that insulin not only maintains endothelial NO production through regulation of 
endothelial nitric oxide synthase (eNOS), but also via the regulation of argininosuccinate 
synthase (AS), which is the rate-limiting step of the citrulline-NO cycle. Using serum 
starved, cultured vascular endothelial cells, we show that insulin up-regulates AS and 
eNOS transcription to support NO production.  Moreover, we show that insulin enhances 
NO production in response to physiological cues such as bradykinin. To translate these 
results to an in vivo model, we show that AS transcription is diminished in coronary 
endothelial cells isolated from rats with streptozotocin (STZ) -induced diabetes.  
Importantly, we demonstrate restoration of AS and eNOS transcription by insulin 
treatment in STZ-diabetic rats, and show that this restoration was accompanied by 
improved endothelial function as measured by endothelium-dependent vasorelaxation.   
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Overall, this report demonstrates, both in cell culture and whole animal studies, that 
insulin maintains vascular function, in part, through the maintenance of AS transcription, 
thus ensuring an adequate supply of arginine to maintain vascular endothelial response to 
physiological cues. 
 
 
Introduction 
 
The hallmark of endothelial dysfunction is the inability of endothelial cells to 
release nitric oxide (NO) in response to physiological cues that promote vasodilation (1).  
NO production in endothelial cells is supported by the citrulline-NO cycle which is 
comprised of three enzymes: the arginine recycling enzymes argininosuccinate synthase 
(AS) and argininosuccinate lyase (AL), and endothelial NO synthase (eNOS) (2).  
Various studies, both in vitro and in vivo, have demonstrated that arginine recycling is 
required for the physiologically regulated production of endothelial NO (3-6).  
 
Endothelial NO is a readily diffusible free radical that stimulates soluble guanylyl 
cyclase in smooth muscle cells to regulate smooth muscle relaxation and blood vessel 
dilation. Consequently, impaired production of NO by endothelial cells contributes to 
hypertension (1).  Since endothelial NO plays a critical physiological role in controlling 
vasodilation, the regulation of eNOS has been extensively investigated to better 
understand the mechanisms which regulate NO production.  Several physiological 
factors, such as acetylcholine, bradykinin, and insulin are known to regulate eNOS to 
increase NO production by vascular tissues.  Acetylcholine and bradykinin are acute 
regulators recognized to promote NO production by increasing eNOS activity through 
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phosphorylation at serine-1177 (bovine S1179) (7, 8).  Insulin is likewise known to 
stimulate eNOS activity to promote NO production through phosphorylation; however, 
insulin has also been acknowledged to support NO production via maintenance of eNOS 
transcription (9, 10).   
 
Importantly, it is also known that the loss of insulin sensitivity, which underlies 
the cause of type 2 diabetes, results in serious vascular complications, including 
hypertension (11).  Because of this, the vasodilatory effects of insulin have been 
extensively studied and shown to be mediated essentially through NO signaling. For 
example, in type 2 diabetes where insulin signaling is impaired (12-14), treatment with 
sodium nitroprusside (SNP), an NO donor, improved vasodilation (15).  The association 
of endothelial dysfunction with type 2 diabetes (16, 17) is further supported by reports 
showing that therapeutic interventions used to alleviate the insulin resistance also 
ameliorated endothelial dysfunction (18, 19).   
 
Unlike eNOS, however, there is a limited understanding of the regulation of AS, 
which catalyzes the rate-limiting step in the citrulline-NO cycle in endothelial cells.  The 
current literature suggests that AS mRNA levels appear to be coordinately regulated by 
physiological factors that regulate eNOS to affect endothelial NO production (20, 21). 
For example, the pro-inflammatory cytokine TNFα has been shown to coordinately 
decrease eNOS and AS transcription in endothelial cells (5), while the PPARγ agonist 
troglitazone, as well as sheer-stress, have been shown to coordinately increase eNOS and 
AS transcription (22).  In the work presented here, we investigated how insulin mediates 
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its effects on the citrulline-NO cycle, not only by affecting eNOS expression, but also AS 
expression in order to ensure that the levels of available arginine are sufficient to support 
eNOS-catalyzed NO production.  To examine this question, we investigated whether 
insulin supports the expression of AS mRNA in vascular endothelial cells; and if so, if 
changes in AS mRNA levels mediated by insulin coordinate with eNOS mRNA levels.  
Two systems were used to investigate this question; cultured bovine aortic vascular 
endothelial cells and coronary endothelial cells isolated from streptozotocin-induced type 
1 diabetic rats. 
 
Experimental procedures 
 
Cell culture  
Bovine aortic endothelial cells (BAEC) were cultured in complete DMEM (1 g/L 
glucose, Mediatech) containing 10% fetal bovine serum (Hyclone Laboratories), 100 
units/ml penicillin and 100 g/ml streptomycin (Mediatech) at 37C and  5% CO2. 
 
Rat STZ-diabetic in vivo model  
Insulin-dependent diabetes was induced in male Sprague-Dawley rats 
(approximately 300 grams) by injecting 65 mg/kg streptozotocin (STZ) (Sigma,  in 0.1 M 
citrate buffer, pH 4.5) into the peritoneal cavity. Control rats received vehicle injection 
only. Three experimental groups of animals were followed for 21 days: (i) STZ-diabetic 
rats (STZ, n = 8); (ii) age-matched control non-diabetic rats treated with vehicle only 
(Controls, n = 16), and (iii) STZ-diabetic rats receiving subcutaneously delivered insulin 
(STZ + INS, n = 4, for each dose). Insulin was delivered via a slow release pellet 
(LinPlant) implanted under the dorsal skin of the neck according to the manufacturer’s 
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(LinShin Canada) instructions. The size of the pellet was chosen to deliver consistent 
daily doses of insulin from 1-5 IU/day, allowing maintainance of normo-glycemia or 
mild to moderate hyperglycemia, if desired, in the animals. The pellets provided insulin 
delivery for up to 56 days. 
 
Non-fasting blood glucose concentration and body weight of all animals were 
measured weekly and when animals were sacrificed. Blood glucose was measured using 
a One-Touch Ultra glucose meter (LifeScan).  At 21 days, animals were euthanized and 
the hearts removed for isolation of coronary endothelial cells (CEC) as described by 
Zuidema et al (23). Briefly, ventricular tissue in 20mM HEPES was digested with 
Liberase Blendzyme 3 (final 0.02-0.07 mg/ml; Roche) and CEC were isolated using 
biotinylated PECAM-1antibody (Sertec) and streptavidin-coated M280 magnetic beads 
(Invitrogen). Endothelial cells bound to beads were isolated using a magnetic stand to 
collect CEC. CEC for total RNA isolation were frozen in RNAlater (Applied 
Biosystems). 
  
NO determinations 
Confluent BAECs were serum starved for 16 hr in DMEM without phenol red, 
and in the presence of 0.1% BSA (Fraction V, Sigma)then treated with 10 nM insulin, 10 
µM bradykinin, both or neither for 4 hours.  The total nitrite from cell culture media was 
measured using the 2,3-diaminonaphthalene (DAN) assay and BMG Fluostar Galaxy 
spectrofluorometer  using an excitation wavelength of 360 nm and emission wavelength 
of 405 nm. (24).  
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Western blot analysis 
BAECs were serum starved as described above followed by treatment with 10 nM 
insulin for 2 hr and then harvested and lysed by scraping in RIPA buffer (1% NP-40, 
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1X protease inhibitors 
(Calbiochem) in PBS). Protein concentrations were determined by BCA assay (Pierce) 
and equal amounts of protein were resolved on 4-15% Tris-HCl SDS-polyacrylamide 
gels (Bio-Rad) and blotted onto Immobilon PVDF (Millipore) for immunoblotting. 
Primary antibodies used include anti-AS and anti-eNOS (BD Transduction Labs) and 
anti-GAPDH (Novus Biologicals). Secondary antibodies used were peroxidase-
conjugated goat anti-mouse or anti-rabbit IgG (Jackson ImmunoResearch Labs). Blots 
were visualized by chemiluminescence using ECL reagent (Pierce) and exposed to film. 
 
RNA isolation and quantitative RT-PCR   
To measure steady state RNA expression of AS and eNOS, total RNA from 
cultured BAEC and isolated rat CEC was isolated using Tri Reagent according to the 
manufacturer’s recommendations (MRC) and as described previously (25). RNA was 
treated with DNase (Ambion) and quantitated  prior to reverse transcription with the High 
Capacity cDNA kit (Applied Biosystems) according to the manufacturer’s instructions. 
Quantitative RT-PCR (qRT-PCR) was performed using the following probe/primer sets: 
bovine AS sense (5´-TCAGCAAGGAGTTTGTGGAGGAGT-3´) AS antisense (5´-
ACACATACTTGGCTCCTTCTCGCT-3´) AS probe (5´-FAM 
ATCCAGTCCAGCGCACTGTACCAGGABHQ-3´); bovine eNOS sense (5´-
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TACATGAGCACGGAGATTGG-3´) and eNOS antisense (5´-
AGCACAGCCAGGTTGATCTC-3´) detected with sybr green; and GAPDH sense (5´-
CATGTTTGTGATGGGCGTGAACCA-3´), GAPDH antisense (5´-
TGATGGCGTGGACAGTGGTCATAA-3´), GAPDH probe (5´-ROXN 
ATTGTCAGCAATGCCTCCTGCACCACCAABHQ-3´). Data for bovine gene 
expression levels was normalized to GAPDH. Rat mRNA levels were detected with the 
following Taqman Gene Expression Assays (Applied Biosystems) AS:  Ass1 
argininosuccinate synthetase 1, Rn00565808_g1; eNOS: Nos3 NO synthase 3, 
Rn02132634_s1; Rplp2: ribosomal protein, large P2, Rn01479927_g1. Data for rat gene 
expression levels was normalized to Rplp2. 
 
Aortic ring preparation and vascular reactivity measurement 
Endothelium-dependent vascular reactivity was assessed as previously described 
(26). Briefly, abdominal aortic rings were fixed on two stainless steel wires, one attached 
to a force transducer and the other attached to a micrometer. The rings were then lowered 
into a bath containing Krebs bicarbonate buffer, equilibrated for 1.5 hours, followed by 
pre-constriction with norepinephrine (10
-6
 mol/L), and the concentration-response 
relationships to acetylcholine (Ach, 10
-10
~10
-6
 mol/L) were determined by cumulative 
addition of Ach in half-log increments directly to the bath. In all rings, NO-mediated 
relaxation was verified at the end of the experiment using 100 mmol/L sodium 
nitroprusside (SNP), a spontaneous NO donor used to assess endothelium-independent 
relaxation of aortic rings.  
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The contraction tension was recorded and vasorelaxation in response to Ach or SNP was 
calculated as percent reduction from norepinephrine-induced tension.  
 
Statistical analysis  
All in vitro data were from at least three independent experiments. Results were 
expressed as the mean +/- standard error.  The student’s t-test was used to note statistical 
significance at p < 0.05 between means of treated and control groups. 
 
Results 
 
Insulin treatment promotes AS and eNOS transcription to support NO production  
Since the expression of AS is necessary to support endothelial NO production (6, 
27-29), we investigated whether the effects of insulin on vascular endothelial NO 
production may be mediated through AS, or whether the increase in NO production was 
simply due to established effects on eNOS activation  (30-32). To examine changes in AS 
transcription that may result from insulin treatment, BAECs were grown to confluence 
and then serum starved for 16 hours before treatment with insulin for 2 hours. RNA was 
prepared and quantitated by qRT-PCR, and as shown in Figure A1A, there was almost a 
2-fold increase in AS mRNA observed after treatment with 10 nM insulin.  Similarly, 
eNOS mRNA levels increased 1.5-fold (near significance) in response to insulin 
treatment, and these results with eNOS were comparable to reported values (33). 
 
With cultured endothelial cells, there was sufficient sample to verify whether 
mRNA levels corresponded to protein levels.  Protein levels of AS and eNOS were 
determined by western blotting and, as shown in Figure A1B & A1C, insulin treatment 
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resulted in an increase in AS and eNOS protein that closely correlated with the 
corresponding mRNA changes. AS and eNOS expression increased 2.2-fold and 2.5-fold, 
respectively, as shown in Figure A2B. These results demonstrated that insulin did indeed 
promote an increase in AS as well as eNOS expression. 
 
To show that up-regulation of AS and eNOS expression by insulin corresponded 
to enhanced production of NO, cultured endothelial cells were treated with insulin under 
basal and stimulatory conditions. BAEC were serum starved for 16 hours and treated with 
or without insulin (10 nM) for 4 hours to measure the effect of insulin on basal NO 
levels. For stimulatory conditions, BAEC were again serum starved for 16 hours, and 
then treated with 10 µM bradykinin, with or without insulin (10 nM), for 4 hours. From 
both determinations, culture media was collected and nitrite, a stable metabolite of NO, 
was measured using the DAN assay.  As shown in Figure A2, no significant change in 
NO production was observed with treatment of insulin alone. However, under the 
stimulatory conditions of 10 µM bradykinin, insulin enhanced the levels of NO produced 
approximately 30% compared to cells treated with bradykinin alone.   
 
Insulin restores AS expression in the streptozotocin-induced diabetic rat  
To ensure that the insulin effects observed in cultured endothelial cells translate to 
vascular endothelial cells from whole animals, we investigated the effects of insulin on 
AS expression in the coronary endothelial cells isolated from STZ -treated diabetic rats.  
The STZ-diabetic rat is a well-characterized animal model of type 1 diabetes mellitus for 
metabolic studies (34, 35) and for evaluation of vascular function (20, 36), allowing us to 
address 1) whether treatment with insulin in STZ-induced diabetic rats restores AS 
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expression, and  2) whether insulin restoration of AS expression restores endothelial 
function. 
 
Because STZ selectively destroys insulin-producing beta cells of the pancreas 
(37), the effects of STZ treatment are to generate an animal which is insulin-dependent. 
This type 1 diabetes was confirmed in each animal by measuring serum glucose levels 
after treatment. Nonfasting hyperglycemia in the STZ-treated rats averaged 586.3 mg/dL 
blood glucose compared to 140.4 mg/dL blood glucose for the untreated, normal animals.  
Correspondingly, the hyperglycemia in the STZ-treated rats decreased with increasing 
doses of insulin that followed STZ treatment.  For the ½ implant (25% normal insulin), 
the average level in blood glucose was found to average 462.8 mg/dL, a 21% reduction in 
blood glucose relative to STZ alone.  For the 1 implant (50% normal insulin) blood 
glucose was reduced, on average, to 315.6 mg/dL for approximately 46% reduction in 
blood glucose; and for the 2 implants (100% normal insulin) the average blood glucose 
was found to be slightly below the values seen in the normal rats, at 124.5 mg/dL (78% 
reduction in blood glucose). 
 
As shown in Figure A3, qRT-PCR on the RNA from isolated coronary endothelial 
cells demonstrated a 50% decrease in AS mRNA levels in the STZ induced diabetic rat 
relative to control animals. A similar decrease, by approximately 20% in eNOS mRNA 
levels, was observed to result from STZ-treatment which was comparable with reported 
literature values (20). Importantly, treatment with insulin was shown to restore both AS 
and eNOS transcription in a dose-dependent fashion, consistent with results from cultured 
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endothelial cells where serum starved levels of AS and eNOS mRNAs were restored by 
treatment with insulin (Figure A1).   
 
Insulin restores acetycholine induced, NO mediated relaxation in vascular rings from 
streptozotocin induced diabetic rats 
To demonstrate that reestablishment of AS and eNOS transcription relates to the 
physiological recovery of endothelial function, vasodilatory studies were carried out on 
isolated aortic rings from the STZ-treated rats.  Not surprisingly, NO-dependent, 
acetylcholine-stimulated vaso-relaxation was shown to be reduced in aortic rings taken 
from STZ-induced diabetic rats compared to those isolated from untreated animals 
(Figure A4). Relaxation values (% of maximal non-endothelium-mediated relaxation by 
SNP) decreased from 61.21 ± 1.62% in the normal animals to 45.31 ± 3.97% in the STZ-
diabetic animals.  However, aortic vessel reactivity was shown to recover in rats treated 
with insulin implants as demonstrated by relaxation values of 54.03 ± 2.41% for ½ 
insulin implant, 70.53 ± 1.58% for 1 insulin implant, and 60.86 ± 2.65% for 2 insulin 
implants. The 1 insulin implant level actually improved vessel function to a greater extent 
than that observed in normal animals, consistent with its reduction in blood glucose. 
 
 
Discussion 
 
Impairment of endothelial NO production plays a pivotal role in the pathogenesis 
of diabetes, compromising endothelial cell regulation of vascular function and 
homeostasis (38). Therefore, deciphering the molecular mechanisms involved in the 
constitutive and stimulated production of NO by vascular endothelial cells is critical to 
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understanding how physiological cues mediate their cardiovascular protective effects, 
thereby maintaining endothelial function, and how risk factors mediate their deleterious 
effects resulting in endothelial dysfunction. 
 
In this study, the enhancement of AS expression by insulin in BAECs was shown 
to correspond to a similarly enhanced expression of eNOS, as well as to an augmented 
response to bradykinin, evidenced by increased NO production relative to bradykinin 
treatment alone. The fact that the response to NO stimulators, such a bradykinin, was 
enhanced by insulin suggests that one action of insulin may be to poise the endothelium 
to more effectively respond to physiological cues by promoting both AS and eNOS 
expression. This is important since the coordinate expression of AS is necessary to 
maintain an adequate source of arginine to support endothelial NO production (6).  If 
arginine availability is limited under conditions of no or limited insulin sensitivity, this 
could lead to enzymatic uncoupling of eNOS with subsequent production of reactive 
oxygen species (39).  
 
Furthermore, using the STZ-treated diabetic rat, we showed that the absence of 
insulin resulted in diminished expression of AS mRNA, as well as eNOS mRNA; the 
latter having been well-established as important to insulin cardioprotective effects (30-
32). The loss of AS expression in coronary endothelial cells from STZ-treated diabetic 
rats suggested that insulin signaling is required to maintain a functional citrulline-NO 
cycle.  Also noted was that aggressive insulin therapy with regards to the STZ-treated 
160 
 
diabetic rats resulted in an increased expression of both eNOS and AS mRNA over that 
of the control with a matching improvement in vascular function. 
 
In summary, this examination of insulin regulation of endothelial AS transcription 
provides an additional level of support for the physiological significance of AS in 
vascular endothelial NO production. These results suggest that insulin preserves optimal 
endothelial function by maintaining the appropriate expression of the major enzymatic 
constituents of the citrulline-NO cycle. 
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Figure A1. Quantitation of eNOS and AS expression in cultured cells by qRT-PCR and 
western blotting.  Confluent BAEC were serum starved for 16 hr and treated with 10 nM 
insulin for 2 hours. Control cells were untreated. (A) Total RNA, isolated from treated 
and control BAEC, was reverse transcribed and AS and eNOS mRNA levels were 
measured relative to GAPDH by qRT-PCR. (B) BAEC were lysed with RIPA buffer, 
equal amounts of protein were separated by SDS PAGE, and standard western blotting 
was performed using anti-AS, anti-eNOS, and anti-GAPDH antibodies. (C) Quantitation 
of the western blots relative to GAPDH expression respectively.  (* p<0.05, ‡p<0.01) 
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Figure A2. Measurement of NO production by stimulated BAEC. Confluent BAEC were 
serum starved 16 hr and NO production was stimulated by 10 µM bradykinin in the 
absence (BK) or presence (BK + INS) of 10 nM insulin for 4 hr.  NO produced was 
compared to insulin alone (INS) and untreated BAEC (control). Total nitrite from cell 
culture media was measured using the 2,3-diaminonaphthalene (DAN) assay. Nitrite 
levels were normalized to total protein and reported as relative change from non-treated 
(control). (*p<0.05) 
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Figure A3. Quantitation of eNOS and AS mRNA expression in streptozotocin-induced 
diabetic rats by qRT- PCR. Streptozotocin-induced diabetic rats were compared to 
normal rats relative to insulin induced expression of AS and eNOS. Diabetic rats were 
randomly divided into four groups (n=4 per group). Three groups of diabetic rats had 
slow-release insulin pellets implanted under the dorsal skin of the neck at a dosage of 
25% normal insulin (1/2 implant), 50% normal insulin (1 implant), and 100% normal 
insulin (2 implant) for 21 days. One group of diabetic rats received no implant (STZ). 
Non-diabetic (Normal) animals also received no implant. Total CEC RNA was reverse 
transcribed and AS and eNOS mRNA levels were quantitated relative to ribosomal 
protein, large P2 (RPLP2). (*p<0.05 compared to control, ‡p<0.05 compared to STZ 
alone) 
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Figure A4. Endothelium-dependent relaxation assessment of vascular rings isolated from 
treated streptozotocin-induced diabetic rats.  Rats were treated as described in Figure 3. 
At 21 days, animals were euthanized and segments of abdominal aorta were dissected for 
vessel reactivity studies. Aortic rings were pre-constricted with norepinephrine and aortic 
vessel reactivity was measured in the presence of increasing concentrations of 
acetylcholine (10-10-10-6 M).  
 
 
